"","Drug","Targets","Disease","Enrichment.biomarker","Marker.type","Biomarker.relationship","Biomarker.logical.conditions","Model","PMID","Article.title","Key.sentence","Pubmed.link","Note","drug_drugbank_standard","drug_pubchem","biomarker_ensembl_standard","diseases_EFO_MONDO_standard","biomarker_term","QC"
"1","CDK4/6 INHIBITORS","CDK4/6","ER+ BREAST CANCER","ESR1, CyclinE1, CyclinE2","protein expression, protein expression, protein expression","positive, positive, positive","AND, AND/OR","patients","32061162","Cyclins E1 and E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.","Cyclin E1 is one the most promising biomarkers in estrogen receptor positive (ER+) breast cancer for response to the new standard of care drug class, CDK4/6 inhibitors.","https://www.ncbi.nlm.nih.gov/pubmed/?term=32061162","This is a review. drug names are not mentioned in the abstract.","NA","NA","ENSG00000091831, NA, NA","EFO_1000650","ESR1 PROTEIN EXPRESSION POSITIVE AND CYCLINE1 PROTEIN EXPRESSION POSITIVE AND/OR CYCLINE2 PROTEIN EXPRESSION POSITIVE","failed drug"
"2","NA",NA,"B-LIKE HER2-NEGATIVE INVASIVE BREAST CANCER","H3K27me3","protein expression","positive",NA,"patients","32050892
","Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence.","H3K27me3 immunoexpression assessed by digital imaging scoring software is an independent prognosis biomarker in luminal-like BC patients","https://www.ncbi.nlm.nih.gov/pubmed/?term=32050892","No drug was mentioned in the abstract.","NA","56956252","NA","EFO_0005537","H3K27ME3 PROTEIN EXPRESSION POSITIVE","failed biomarker"
"3","NA",NA,"BREAST CANCER","miR-21, miR-23a, miR-34a,miR-1, miR-10b, miR-16","mRNA","positive，positive，positive，positive，positive，positive","OR, OR, OR,OR,         OR,OR","patients","32044304","Cell-free miRNAs as non-invasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction.","Numerous studies have found a distinct expression profile of circulating miRNAs in breast tumour versus non-tumour and in early and advanced-stage","https://www.ncbi.nlm.nih.gov/pubmed/?term=32044304","This is a review. no drug was mentioned in the abstract.","NA","56956252","ENSG00000284190, NA, NA, ENSG00000272920, NA, NA","MONDO_0007254","failed","failed term"
"4","NA",NA,"TRIPLE-NEGATIVE BREAST CANCER (TNBC)","ESR, PGR, ERBB2, GD3s","Protein expression, Protein expression,Protein expression, Protein and mRNA expression, gene methylation","negative,negative,negative, positive","AND,         AND,          AND","cell line, patients","32042739","Epigenetic hypomethylation and upregulation of GD3s in triple negative breast cancer.","Overexpression of GD3s in human breast cancer cells increased their proliferation, migration, invasion and colony formation ability. GD3s expression in breast cancers was closely associated with relapse-free survival (RFS) and overall survival (OS).","https://www.ncbi.nlm.nih.gov/pubmed/?term=32042739","This is a review. no drug was mentioned in the abstract.","NA","56956252","ENSG00000091831, ENSG00000082175, ENSG00000141736, NA","MONDO_0007254","failed","failed term"
"5","NA",NA,"LUMINAL B AND HER2 BREAST CANCER","Annexin 2","protein expression","positive",NA,"patients","32072035","Annexin 2 protein expression is associated with breast cancer subtypes in African American women.","ANX2 might be a biomarker of aggressiveness and a relevant candidate biomarker in high risk African American women with Luminal B and HER2 breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/32072035","No drug was mentioned in the abstract.","NA","56956252","ENSG00000182718","MONDO_0007254","ANNEXIN 2 PROTEIN EXPRESSION POSITIVE","pass"
"6","NA",NA,"BREAST CANCER","SLX4IP","protein expression","SLX4IP positive",NA,"mouse","32071280","SLX4IP and telomere dynamics dictate breast cancer metastasis and therapeutic responsiveness.","This study illuminates SLX4IP as a potential predictive biomarker for breast cancer progression and metastatic relapse. ","https://www.ncbi.nlm.nih.gov/pubmed/32071280","No drug was mentioned in the abstract.","NA","56956252","ENSG00000149346","MONDO_0007254","SLX4IP PROTEIN EXPRESSION SLX4IP POSITIVE","pass"
"7","NA",NA,"BREAST CANCER","FUT3","protein expression","high FUT3 levels",NA,"patients","32062822","High FUT3 expression is a marker of lower overall survival of breast cancer patients.","Our analysis showed that high FUT3 levels were consistently associated to reduced invasive breast cancer patients overall survival. ","https://www.ncbi.nlm.nih.gov/pubmed/32062822","No drug was mentioned in the abstract.","NA","56956252","ENSG00000171124","MONDO_0007254","FUT3 PROTEIN EXPRESSION HIGH FUT3 LEVELS","pass"
"8","NA",NA,"TNBC","FRα","protein expression","FRα positive",NA,"patients","32047850","Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients.","The results demonstrate the potential of targeting the FRα in the majority of TNBC patients and suggest that variable expression may point to a need to stratify on FRα expression in clinical studies.","https://www.ncbi.nlm.nih.gov/pubmed/32047850","No drug was mentioned in the abstract.","NA","56956252","NA","NA","FRΑ PROTEIN EXPRESSION FRΑ POSITIVE","failed biomarker,failed disease"
"9","NA",NA,"BREAST CANCER","DEGS","gene expression","positive",NA,"patients","32044879","Differentially Expressed Genes in Matched Normal, Cancer, and Lymph Node Metastases Predict Clinical Outcomes in Patients With Breast Cancer.","The DEGs identified in this study represent novel biomarkers for predicting the prognosis of patients with BC.","https://www.ncbi.nlm.nih.gov/pubmed/32044879","No drug was mentioned in the abstract.","NA","56956252","ENSG00000143753","MONDO_0007254","DEGS GENE EXPRESSION POSITIVE","pass"
"10","NA",NA,"BREAST CANCER","TILs,CD4,CD8,CD20,CD68","gene expression, gene expression, gene expression, gene expression, gene expression","positive, negative, negative, negative, negative","AND, AND, AND, AND","patients","32044815","Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.","Subtypes of TILs in RT is a potential predictive biomarker of survival in TNBC patients after NAC.","https://www.ncbi.nlm.nih.gov/pubmed/32044815","No drug was mentioned in the abstract.","NA","56956252","NA, ENSG00000010610, ENSG00000153563, ENSG00000156738, ENSG00000129226","MONDO_0007254","TILS GENE EXPRESSION POSITIVE AND CD4 GENE EXPRESSION NEGATIVE AND CD8 GENE EXPRESSION NEGATIVE AND CD20 GENE EXPRESSION NEGATIVE AND CD68 GENE EXPRESSION NEGATIVE","failed biomarker"
"11","NA",NA,"BREAST CANCER","ER, PR, HER2, CDC20, BIRC5","protein expression, protein expression,  protein expression, protein expression","positive, positive, positive, positive, positive","AND, AND, AND, AND","patients","32043523","Identification of prognostic significance of BIRC5 in breast cancer using integrative bioinformatics analysis.","BIRC5 may be adopted as a promising predictive marker and potential therapeutic target in breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/32043523","No drug was mentioned in the abstract.","NA","56956252","ENSG00000091831, ENSG00000134551, ENSG00000141736, ENSG00000117399, ENSG00000089685","MONDO_0007254","failed","failed term"
"12","NA",NA,"BREAST CANCER，TNBC,NON-TNBC","TFF1","protein expression","TFF1 overexpression",NA,"patients","31986408","Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers","Expression of TFF1 was associated with clinical characters of patients with BC. Serum TFF1 could be used to predict prognosis of patients with BC, especially non-TNBC","https://www.ncbi.nlm.nih.gov/pubmed/?term=31986408","No drug was mentioned in the abstract.","NA","56956252","ENSG00000160182","MONDO_0007254","TFF1 PROTEIN EXPRESSION TFF1 OVEREXPRESSION","pass"
"13","NA",NA,"BREAST CANCER","CK19,CLEC3E,KLK11","gene expression","positive, positive, positive","OR, OR, OR","patients","31983196","Novel Biomarkers Aim at Detecting Metastatic Sentinel Lymph Nodes in Breast Cancer","Regarding the findings, CLEC3A along with CK19 can be used as a promising marker with high sensitivity and specificity for the detection of metastatic SLN.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31983196","No drug was mentioned in the abstract.","NA","56956252","ENSG00000171345, NA, ENSG00000167757","MONDO_0007254","failed","failed term"
"14","NA",NA,"BREAST CANCER","TP53","gene expression","TP53 deficiency or silence",NA,"patients","31983017","The novel TP53 3'-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection","The 3'-end methylation of TP53 might be a crucial regulator for its expression in breast cancer, suggesting that TP53 3'-end hyper-methylation associated with its lower expression could be a potential biomarker for breast cancer diagnosis. ","https://www.ncbi.nlm.nih.gov/pubmed/?term=31983017","No drug was mentioned in the abstract.","NA","56956252","ENSG00000141510","MONDO_0007254","TP53 GENE EXPRESSION TP53 DEFICIENCY OR SILENCE","pass"
"15","NA",NA,"BREAST CANCER , INVASIVE DUCTAL CARCINOMA (IDC)","MCM3,Ki67,ER,HER2","protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive, positive","OR, AND, AND, AND","patients","31980982","Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients","COL1A1 and MCM3 were significantly up-regulated in IDC tissues, of which only MCM3 was related to cell proliferation.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31980982",NA,"NA","56956252","ENSG00000112118, ENSG00000148773, ENSG00000091831, ENSG00000141736","EFO_0000186","failed","failed term"
"16","NA",NA,"BREAST CANCER","hs-cTnT, NT-proBNP","protein expression, protein expression","positive, positive","AND","patients","31959034","Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.","Cardiovascular biomarkers may play an important role in CTRCD risk prediction in patients with breast cancer who receive cardiotoxic cancer therapy, particularly in those treated with sequential anthracycline and trastuzumab therapy","https://www.ncbi.nlm.nih.gov/pubmed/?term=31959034","No drug was mentioned in the abstract.","NA","56956252","NA, NA","MONDO_0007254","HS-CTNT PROTEIN EXPRESSION POSITIVE AND NT-PROBNP PROTEIN EXPRESSION POSITIVE","failed biomarker"
"17","NA",NA,"BREAST CANCER, TBNC","BRCAness","mutation","mutation",NA,"patients","31958182","Using Next generation Sequencing to Redefine BRCAness in Triple-Negative Breast Cancer.","The sequencing results showed that 13, 14, and 14 patients had BRCA, non-BRCA HR gene, and non-HR DDR gene mutations, respectively. aCGH revealed that BRCA-mutated and HR gene-mutated TNBC shared similar BRCAness features","https://www.ncbi.nlm.nih.gov/pubmed/?term=31958182","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","BRCANESS MUTATION MUTATION","failed biomarker"
"18","NA",NA,"BREAST CANCER","cytokeratin 18/19,N-cadherin, vimentin, plastin-3","protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive","OR, AND, AND","patients","31947504","N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study.","N-cadherin mRNA levels in blood may serve as a novel prognostic biomarker predicting NM, including recurrence, in breast cancer patients.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31947504","No drug was mentioned in the abstract.","NA","56956252","NA, ENSG00000170558, ENSG00000026025, ENSG00000102024","MONDO_0007254","CYTOKERATIN 18/19 PROTEIN EXPRESSION POSITIVE OR N-CADHERIN PROTEIN EXPRESSION POSITIVE AND VIMENTIN PROTEIN EXPRESSION POSITIVE AND PLASTIN-3 PROTEIN EXPRESSION POSITIVE","failed biomarker"
"19","NA",NA,"BREAST CANCER","Twist","gene expression","Twist overexpression",NA,"patients","31942413","TWIST1 Gene Expression as a Biomarker for Predicting Primary Doxorubicin Resistance in Breast Cancer","There was a significant difference in TWIST gene expression between responder and non responder tumors . The TWIST gene expression of the drug-resistant group was higher than the responsive group","https://www.ncbi.nlm.nih.gov/pubmed/?term=31942413",NA,"NA","56956252","ENSG00000122691","MONDO_0007254","TWIST GENE EXPRESSION TWIST OVEREXPRESSION","pass"
"20","NA",NA,"TNBC","CD163, PD-L1","gene expression, gene expression","positive, positive","AND, AND","patients","31937323","Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.","Metaplastic breast cancer samples demonstrated greater amount of CD163 in the stroma and PD-L1 in the tumor than triple-negative breast cancer samples, although more triple-negative breast cancer samples were positive for CD8 in the tumor than metaplastic breast cancer samples","https://www.ncbi.nlm.nih.gov/pubmed/?term=31937323","No drug was mentioned in the abstract.","NA","56956252","ENSG00000177575, ENSG00000120217","NA","failed","failed disease,failed term"
"21","NA",NA,"TNBC","MALAT1, BACH1","gene expression, gene expression","positive, positive","AND","patients","31939443","MALAT1 and BACH1 are prognostic biomarkers for triple-negative breast cancer","MALAT1 and BACH1 expression was significantly correlated with tumor-node-metastasis stage, distant metastasis, pathological stage, and survival outcomes of patients. Patients with high MALAT1 and BACH1 expression exhibited shorter overall survival and disease-free survival.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31939443","No drug was mentioned in the abstract.","NA","56956252","ENSG00000251562, ENSG00000136492","NA","MALAT1 GENE EXPRESSION POSITIVE AND BACH1 GENE EXPRESSION POSITIVE","failed disease"
"22","NA",NA,"LOCALLY ADVANCED BREAST CANCER","LRR-NRR-MRR","others","positive",NA,"patients","32042669","Novel lymphocyte to red blood cell ratio (LRR), neutrophil to red blood cell ratio (NRR), monocyte to red blood cell ratio (MRR) as predictive and prognostic biomarkers for locally advanced breast cancer.","The LRR-NRR-MRR score could be identified as a new predictive biomarker for the therapeutic effect of neoadjuvant therapy and an independent prognostic factor for both DFS and OS for locally advanced breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/32042669","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","LRR-NRR-MRR OTHERS POSITIVE","failed biomarker"
"23","NA",NA,"BREAST CANCER","SETD 3","protein expression","SETD3 overexpression",NA,"patients","32042016","SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells.","Our study suggests that SETD3 expression can act as a subtype-specific biomarker for breast cancer progression and prognosis.","https://www.ncbi.nlm.nih.gov/pubmed/32042016","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","SETD 3 PROTEIN EXPRESSION SETD3 OVEREXPRESSION","failed biomarker"
"24","NA",NA,"BREAST CANCER","TUSC 8","lncRNA","positive",NA,"patients","32039833","Long non-coding RNA TUSC8 inhibits breast cancer growth and metastasis via miR-190b-5p/MYLIP axis.","These results suggested that TUSC8 inhibited breast cancer growth and metastasis via miR-190b-5p/MYLIP axis","https://www.ncbi.nlm.nih.gov/pubmed/32039833","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","TUSC 8 LNCRNA POSITIVE","failed biomarker"
"25","NA",NA,"BREAST CANCER","miR-21, miR-125b, miR-100, miR-425-5p, miR-200c, miR-183, miR-182","gene expression, gene expression, gene expression, gene expression, gene expression, gene expression, gene expression, gene expression","positive, negative, negative, positive, positive, positive, positive, positive","AND, AND, AND, AND, OR, OR","patients","32040529","miRNA expression in advanced Algerian breast cancer tissues","The objective of this study is to explore the expression of several miRNAs reported to be deregulated in breast cancer. ","https://www.ncbi.nlm.nih.gov/pubmed/32040529","No drug was mentioned in the abstract.","NA","56956252","ENSG00000284190, NA, NA, NA, NA, NA, ENSG00000207990","MONDO_0007254","failed","failed term"
"26","NA",NA,"BREAST CANCER","ERBB2","protein expression","negative",NA,"patients","32036454","New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified.","confirm the prevalence of abnormal HER2 signaling amongst HER2-negative breast cancer patients (HER2-/HSFs+).","https://www.ncbi.nlm.nih.gov/pubmed/32036454","No drug was mentioned in the abstract.","NA","56956252","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"27","NA",NA,"BREAST CANCER","PPEF 1","protein expression","positive",NA,"patients","32021267","The Clinical Significance of PPEF1 as a Promising Biomarker and Its Potential Mechanism in Breast Cancer.","PPEF1 exerted a tumorigenic role and involved in molecular mechanism of tumorigenesis in BC which served as a promising biomarker for prognosis and diagnosis.","https://www.ncbi.nlm.nih.gov/pubmed/32021267","No drug was mentioned in the abstract.","NA","56956252","ENSG00000086717","MONDO_0007254","PPEF 1 PROTEIN EXPRESSION POSITIVE","pass"
"28","NA",NA,"BREAST CANCER","TP53TG1，Rp5-1061H20.4","gene expression, gene expression,","positive, positive","AND","patients","32020607","Survival analysis for long noncoding RNAs identifies TP53TG1 as an antioncogenic target for thebreast cancer.","TP53TG1, Rp5-1061H2. 4 are lncRNAs that are significantly related to the prognosis of breast cancer and are regulated by methylation status.","https://www.ncbi.nlm.nih.gov/pubmed/32020607","No drug was mentioned in the abstract.","NA","56956252","ENSG00000182165, NA","MONDO_0007254","TP53TG1 GENE EXPRESSION POSITIVE AND RP5-1061H20.4 GENE EXPRESSION POSITIVE","pass"
"29","NA",NA,"TNBC","ADAM 12","protein expression","ADAM12 silencing",NA,"patients","32019179","ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-NegativeBreast Cancer.","Our results indicate that ADAM12 is a potential therapeutic target and its hypomethylation could be a poor outcome biomarker in TNBC.","https://www.ncbi.nlm.nih.gov/pubmed/32019179","No drug was mentioned in the abstract.","NA","56956252","NA","NA","ADAM 12 PROTEIN EXPRESSION ADAM12 SILENCING","failed biomarker,failed disease"
"30","NA",NA,"LABC","CfDNA","DNA","positive",NA,"patients","32017472","Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer.","cfDNA was suggested to be a promising diagnostic indicator.","https://www.ncbi.nlm.nih.gov/pubmed/32017472",NA,"NA","56956252","NA","NA","CFDNA DNA POSITIVE","failed biomarker,failed disease"
"31","NA",NA,"TNBC","BRCA","mutation","positve",NA,"patients","32013831","BRCA Mutational Status is a Promising Predictive Biomarker for Platinum-based Chemotherapy in Triple-Negative Breast Cancer.","The BRCA mutation status has the potential to be a predictive biomarker for platinum-based chemotherapy in TNBC.","https://www.ncbi.nlm.nih.gov/pubmed/32013831","No drug was mentioned in the abstract.","NA","56956252","ENSG00000012048","NA","BRCA MUTATION POSITVE","failed disease"
"32","NA",NA,"BREAST CANCER","CMTMs","protein expression","positive",NA,"patients","31998718","Bioinformatics-Based Discovery of CKLF-Like MARVEL Transmembrane Member 5 as a Novel Biomarker for Breast Cancer.","Our findings indicate that CMTM5 can be used as a prognostic biomarker and potential therapeutic target for breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/31998718","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","CMTMS PROTEIN EXPRESSION POSITIVE","failed biomarker"
"33","NA",NA,"BREAST CANCER","XIST，TSIX","gene expression, gene expression,","positive, positive","MISSING","patients","31998636","XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients.","This correlative study has shed light on the role of both lncRNAs XIST and TSIX as potential non-invasive BC immune biomarkers.","https://www.ncbi.nlm.nih.gov/pubmed/31998636","No drug was mentioned in the abstract.","NA","56956252","ENSG00000229807, ENSG00000270641","MONDO_0007254","XIST GENE EXPRESSION POSITIVE MISSING TSIX GENE EXPRESSION POSITIVE","pass"
"34","NA",NA,"BREAST CANCER","BRCA1, BRCA2","mutation,mutation","positive, positive","OR","patients","31998560","Differentially expressed genes and key molecules of BRCA1/2-mutant breast cancer: evidence from bioinformatics analyses.","Our research provides comprehensive and new insights for the identification of biomarkers connected with BRCA mutations, availing diagnosis and treatment of breast cancer and BRCA1/2-mutant breast cancer patients.","https://www.ncbi.nlm.nih.gov/pubmed/31998560","No drug was mentioned in the abstract.","NA","56956252","ENSG00000012048, ENSG00000139618","MONDO_0007254","BRCA1 MUTATION POSITIVE OR BRCA2 MUTATION POSITIVE","pass"
"35","NA",NA,"BREAST CANCER","HER2, LINC 00520 ( rs8012083)","protein expression,  gene expression","positive, positive,  positive, positive","AND","patients","31997582","Characterization of lncRNA LINC00520 and functional polymorphisms associated with breast cancer susceptibility in Chinese Han population.","The genetic variant of LINC00520 was related to the susceptibility of BC","https://www.ncbi.nlm.nih.gov/pubmed/31997582","No drug was mentioned in the abstract.","NA","56956252","ENSG00000141736, NA","MONDO_0007254","failed","failed term"
"36","NA",NA,"TAMOXIFEN TREATED BREAST CANCER","SPP1/osteopontin","protein expression","positive",NA,"patients","31996744","Evaluation of SPP1/osteopontin expression as predictor of recurrence in tamoxifen treated breast cancer.","This indicates that SPP1 mRNA is a stronger prognostic marker compared to tumor tissue OPN protein.","https://www.ncbi.nlm.nih.gov/pubmed/31996744",NA,"NA","56956252","NA","MONDO_0007254","SPP1/OSTEOPONTIN PROTEIN EXPRESSION POSITIVE","failed biomarker"
"37","NA",NA,"TRIPLE-NEGATIVE BREAST CANCER","ESR1, PGR, ERBB2, Exo-AnxA 2","protein expression，protein expression, protein expression, protein expression","negative, negative, negative, positive","AND,AND,AND","patients","31992335","Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis.","Our results demonstrated that the expression of serum exo-AnxA2 is high in AA women with TNBC and promotes angiogenesis.","https://www.ncbi.nlm.nih.gov/pubmed/31992335","No drug was mentioned in the abstract.","NA","56956252","ENSG00000091831, ENSG00000082175, ENSG00000141736, NA","EFO_0005537","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND EXO-ANXA 2 PROTEIN EXPRESSION POSITIVE","pass"
"38","NA",NA,"BREAST CANCER","ZNF367","gene expression","positive",NA,"patients","31988454","Zinc finger protein 367 promotes metastasis by inhibiting the Hippo pathway in breast cancer."," Our findings addressed the importance of ZNF367 in breast cancer as a prognostic biomarker and offered a potential therapeutic strategy for the treatment of a subset of metastatic breast cancer with ZNF367 overexpression.","https://www.ncbi.nlm.nih.gov/pubmed/31988454","No drug was mentioned in the abstract.","NA","56956252","ENSG00000165244","MONDO_0007254","ZNF367 GENE EXPRESSION POSITIVE","pass"
"39","NA",NA,"BREAST CANCER","PON1-L55M","polymorphism","positive",NA,"patients","31983193","Association of PON1-L55M Genetic Variation and Breast Cancer Risk: A Case-Control Trial.","Our results suggest that the PON1-L55M genetic variation could be a genetic risk factor for breast cancer risk and it could be considered as a molecular biomarker for screening of susceptible women.","https://www.ncbi.nlm.nih.gov/pubmed/31983193","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","PON1-L55M POLYMORPHISM POSITIVE","failed biomarker"
"40","NA",NA,"TNBC","FABP7,ART3,CT83,TTYH1","gene expression, gene expression, gene expression, gene expression,","positive, positive,  positive, positive","AND, AND, AND","patients","31974598","Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.","In conclusion, this study identified FABP 7 and CT83 key genes as potential biomarkers involved in TNBC","https://www.ncbi.nlm.nih.gov/pubmed/31974598","No drug was mentioned in the abstract.","NA","56956252","ENSG00000164434, ENSG00000156219, ENSG00000204019, ENSG00000167614","NA","FABP7 GENE EXPRESSION POSITIVE AND ART3 GENE EXPRESSION POSITIVE AND CT83 GENE EXPRESSION POSITIVE AND TTYH1 GENE EXPRESSION POSITIVE","failed disease"
"41","NA",NA,"BREAST CANCER","LINC01140","lncRNA","LINC01140 
overexpression",NA,"patients","31966045","Downregulation of LINC01140 is associated with adverse features of breast cancer.","LINC01140 may be a potential biomarker for the prognosis of patients with BC. ","https://www.ncbi.nlm.nih.gov/pubmed/31966045","No drug was mentioned in the abstract.","NA","56956252","ENSG00000267272","MONDO_0007254","LINC01140 LNCRNA LINC01140 
OVEREXPRESSION","pass"
"42","NA",NA,"BREAST CANCER","circ_0007255","RNA","circ_0007255 absence",NA,"patients","31962380","Circular RNA 0007255 regulates the progression of breast cancer through miR-335-5p/SIX2 axis.","Circ_0007255 functioned as a novel oncogene in the progression of BC by regulating miR-335-5p/SIX2 axis, and might be a promising biomarker for BC treatment.","https://www.ncbi.nlm.nih.gov/pubmed/31962380","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","CIRC_0007255 RNA CIRC_0007255 ABSENCE","failed biomarker"
"43","NA",NA,"BREAST CANCER","CUGB 1,IR-A","gene expression, gene expression,","positive, positive,","AND","cells","31958132","RNA-binding protein CUGBP1 controls the differential INSR splicing in molecular subtypes ofbreast cancer cells and affects cell aggressiveness.","Our data revealed the predominant mitogenic role of IR-A isoform inbreast cancer and depicted a novel interplay between INSR and CUGBP1, implicating CUGBP1 and IR-A isoform as the potential therapeutic targets and biomarkers for breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/31958132","No drug was mentioned in the abstract.","NA","56956252","NA, NA","MONDO_0007254","CUGB 1 GENE EXPRESSION POSITIVE AND IR-A GENE EXPRESSION POSITIVE","failed biomarker"
"44","NA",NA,"BREAST CANCER","MRPS 23","gene expression","positive",NA,"patients","31950385","MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes.","Amplification of MRPS23 is associated with higher proliferation and non-basal subtypes in breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/31950385","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","MRPS 23 GENE EXPRESSION POSITIVE","failed biomarker"
"45","NA",NA,"BREAST CANCER","SPRY4-IT1","gene expression","positive",NA,"patients","31933911","Upregulation of the long non-coding RNA SPRY4-IT1 predicts poor prognosis in breast cancer.","SPRY4-IT1 expression is an independent prognostic factor for patients with BC and may serve as a potential biomarker to predict prognosis in BC patients.","https://www.ncbi.nlm.nih.gov/pubmed/31933911","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","SPRY4-IT1 GENE EXPRESSION POSITIVE","failed biomarker"
"46","NA",NA,"BREAST CANCER","Mir-335，MMP 2，MMP 9","protein expression, protein expression, protein expression","positive, positive, positive","AND, AND","patients","31922434","Expression of MiR-335 and its target metalloproteinase genes: clinical significance in breast cancer.","MiR-335, MMP2, and MMP9 can be used as diagnostic markers in breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/31922434","No drug was mentioned in the abstract.","NA","56956252","NA, ENSG00000035862, ENSG00000157150","MONDO_0007254","MIR-335 PROTEIN EXPRESSION POSITIVE AND MMP 2 PROTEIN EXPRESSION POSITIVE AND MMP 9 PROTEIN EXPRESSION POSITIVE","failed biomarker"
"47","NA",NA,"BREAST CANCER","HMGB 1","protein expression","positive",NA,"patients","31914536","Expression of HMGB1 protein in breast cancer and its clinicopathological significance.","Nuclear and cytoplasmic HMGB1 proteins are related to multiple poor prognostic factors in breast cancer, and may be a potential biomarkerfor breast cancer treatment.","https://www.ncbi.nlm.nih.gov/pubmed/31914536","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","HMGB 1 PROTEIN EXPRESSION POSITIVE","failed biomarker"
"48","NA",NA,"HER2-POSITIVE METASTATIC BREAST CANCER","sHER 2，CA 15.3，CEA","protein expression","positive, positive, positive","AND, AND","patients","31910438","An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.","The results show that regular measurement of sHER2, CA15.3, and CEA levels is useful for predicting the therapeutic response and for monitoring HER2-targeted therapy in patients with HER2-positive metastatic breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/31910438",NA,"NA","56956252","NA, ENSG00000185499, ENSG00000105388","MONDO_0007254","failed","failed biomarker,failed term"
"49","NA",NA,"TNBC","FAK","protein expression","positive",NA,"cells","31905966","Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.","our findings show that CIK cell therapy combined with FAK inhibitors may be a novel therapeutic strategy for patients with TNBC.","https://www.ncbi.nlm.nih.gov/pubmed/31905966","No drug was mentioned in the abstract.","NA","56956252","ENSG00000169398","NA","FAK PROTEIN EXPRESSION POSITIVE","failed disease"
"50","NA",NA,"BREAST CANCER","miR-383-5p","gene expression","miR-383-5p
overexpression",NA,NA,"31903982","MicroRNA-383-5p acts as a potential prognostic biomarker and an inhibitor of tumor cell proliferation, migration, and invasion in breast cancer.","miR-383-5p may be a prognostic biomarker and therapeutic target for breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/31903982","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","MIR-383-5P GENE EXPRESSION MIR-383-5P
OVEREXPRESSION","failed biomarker"
"51","NA",NA,"BREAST CANCER","DNAJC 10(ERDJ 5)","gene expression","positive",NA,"mouse","31902119","Downregulation of DNAJC10 (ERDJ5) is associated with poor survival in breast cancer.","The results of this study indicate that DNAJC10 is a potential diagnostic / prognostic biomarker and tumor suppressor for breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/31902119","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","DNAJC 10(ERDJ 5) GENE EXPRESSION POSITIVE","failed biomarker"
"52","NA",NA,"BREAST CANCER","GALNT 6-LGALS3bp","protein expression","positive",NA,"cells","31894262","The GALNT6‑LGALS3BP axis promotes breast cancer cell growth.","The findings of the present study suggest that the GALNT6‑LGALS3BP axis is crucial for breast cancer cell proliferation and may be a therapeutic target and biomarker for mammary tumors.","https://www.ncbi.nlm.nih.gov/pubmed/31894262","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","GALNT 6-LGALS3BP PROTEIN EXPRESSION POSITIVE","failed biomarker"
"53","NA",NA,"TNBC","BRCA mutational status, HRD score and immune component of the tumor ecosystem","mutation，others","positive, positive","missing",NA,"32052646","Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.","BRCA mutational status, HRD score and immune component of the tumor ecosystem have been explored as potential predictive biomarkers.","https://www.ncbi.nlm.nih.gov/pubmed/?term=32052646",NA,"NA","56956252","NA, NA","NA","BRCA MUTATIONAL STATUS MUTATION POSITIVE MISSING HRD SCORE AND IMMUNE COMPONENT OF THE TUMOR ECOSYSTEM OTHERS POSITIVE","failed biomarker,failed disease"
"54","CDK4/6 INHIBITORS","CDK4/6","HORMONE RECEPTOR-POSITIVE BREAST CANCER","CDK 7, CDK 8, CDK 9, CDK 12, CDK 13","gene expression","positive, positive, positive, positive","AND, AND, AND, AND","patients","32071145","Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.","Some studies now point to potential therapeutic opportunities by inhibiting the transcription-associated CDKs as well as therapeutic vulnerabilities with PARP inhibitors and immunotherapy in tumors deficient in these CDKs.","https://www.ncbi.nlm.nih.gov/pubmed/?term=32071145",NA,"NA","NA","NA, NA, NA, NA, NA","MONDO_0007254","failed","failed drug,failed biomarker,failed term"
"55","NA",NA,"BREAST CANCER","ABC","gene expression，polymorphism",NA,NA,"patients","32010961","Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.","Multidrug resistance transporters combine with more than 100 clinically relevant drugs and affect their handling and pharmacokinetics.","https://www.ncbi.nlm.nih.gov/pubmed/?term=32010961",NA,"NA","56956252","ENSG00000167972","MONDO_0007254","failed","failed term"
"56","BEVACIZUMAB",NA,"BREAST CANCER","HSP27","protein expression",NA,NA,"patients","31989465","HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?","The results of this study suggested that testing for HSP27 expression before administering bevacizumab is not cost effective compared with treat-all with bevacizumab without testing.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31989465",NA,"DB00112","NA","ENSG00000169271","MONDO_0007254","HSP27 PROTEIN EXPRESSION NA","pass"
"57","PALBOCICLIB, RIBOCICLIB, ABEMACICLIB","CDK4/6","BREAST CANCER","CDK4，CDK6","protein expression","positive, positive","AND","patients","31909732","The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer.","This review summarizes the development status of CDK4 / 6i biomarker testing in clinical trials and clinical trials.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31909732",NA,"DB09073,DB11730,DB12001","11478676, 44631912, 46220502","ENSG00000135446, ENSG00000105810","MONDO_0007254","failed","failed term"
"58","TRASTUZUMAB",NA,"BREAST CANCER","ERBB2","protein expression","positive",NA,"patients","31895768","Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report.","In patients with HER2 ++ advanced breast cancer, intrathecal treatment with anti-HER2 therapy (trastuzumab) is feasible.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31895768",NA,"DB00072","3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"59","CHEMOTHERAPY, TRASTUZUMAB, LAPATINIB",NA,"BREAST CANCER","Rbsig,ERBB2,HR","gene expression, protein expression, protein expression,","positive, positive, positive","AND, AND","patients","31853266","An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06).","pCR rate was significantly higher in patients with RBsig High tumours than those with RBsig Low (35% versus 18% respectively; p = 0.01).","https://www.ncbi.nlm.nih.gov/pubmed/?term=31853266",NA,"NA,DB00072,DB01259","94994, 3001322, 208908","NA, ENSG00000141736, ENSG00000168453","MONDO_0007254","RBSIG GENE EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION POSITIVE AND HR PROTEIN EXPRESSION POSITIVE","failed biomarker"
"60","TRASTUZUMAB",NA,"ADVANCED GASTRIC CANCER","ERBB2 ","protein expression","positive",NA,"patients","31892554","Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.","HER2 expression can change after trastuzumab-based chemotherapy in patients with advanced HER2-positive gastric cancer.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31892554",NA,"DB00072","3001322","ENSG00000141736","MONDO_0001056","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"61","NA",NA,"TRIPLE-NEGATIVE BREAST CANCER","ESR1, PGR, ERBB2, BRCA","protein expression, protein expression, protein expression, mutation","negative, negative, negative, positive","MISSING, MISSING, MISSING","patients","32052646","Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.","BRCA mutational status, HRD score and immune component of the tumor ecosystem have been explored as potential predictive biomarkers.","https://www.ncbi.nlm.nih.gov/pubmed/?term=32052646",NA,"NA","56956252","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000012048","EFO_0005537","ESR1 PROTEIN EXPRESSION NEGATIVE MISSING PGR PROTEIN EXPRESSION NEGATIVE MISSING ERBB2 PROTEIN EXPRESSION NEGATIVE MISSING BRCA MUTATION POSITIVE","pass"
"62","PROPRANOLOL","β-adrenergic receptor","BREAST CANCER","β-adrenergic receptor","missing","positive",NA,NA,"32029438","Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?","Blockade of the β-adrenergic receptor signaling with propranolol, along with potential future combinatorial strategies, holds promise for reducing breast cancer progression and metastasis.","https://www.ncbi.nlm.nih.gov/pubmed/?term=32029438",NA,"DB00571","62882","NA","MONDO_0007254","Β-ADRENERGIC RECEPTOR MISSING POSITIVE","failed biomarker"
"63","NA",NA,"BREAST CANCER","DNA methylation","methylation","positive",NA,"patients","32019269","Computational Detection of Breast Cancer Invasiveness with DNA Methylation Biomarkers.","This study demonstrates DNA methylation as a potential biomarker to predict breast tumor invasiveness and as a possible parameter that could be included in the studies aiming to predict breast cancer aggressiveness.","https://www.ncbi.nlm.nih.gov/pubmed/?term=32019269",NA,"NA","56956252","NA","MONDO_0007254","DNA METHYLATION METHYLATION POSITIVE","failed biomarker"
"64","NA",NA,"TRIPLE NEGATIVE BREAST CANCER","BRCA","mutation","positive",NA,"patients","32013831","BRCA Mutational Status is a Promising Predictive Biomarker for Platinum-based Chemotherapy in Triple-Negative Breast Cancer.","With the emergence of genetic testing, several recent studies suggested mutations in breast cancer susceptibility gene (BRCA) in TNBC patients as important predictors of outcomes.","https://www.ncbi.nlm.nih.gov/pubmed/?term=32013831",NA,"NA","56956252","ENSG00000012048","EFO_0005537","BRCA MUTATION POSITIVE","pass"
"65","CAPECITABINE",NA,"TRIPLE NEGATIVE BREAST CANCER","ESR1, PGR, ERBB2","protein expression, protein expression, protein expression","negative, negative, negative,","MISSING, MISSING","patients","32005747","Predictive biomarkers for adjuvant capecitabine benefit in early stage triple negative breast cancer in the FinXX clinical trial.","Genes and metagenes related to anti-tumor immunity, immune response and capecitabine activation could identify TNBC patients who are more likely to benefit from adjuvant capecitabine. ","https://www.ncbi.nlm.nih.gov/pubmed/?term=32005747",NA,"DB01101","60953","ENSG00000091831, ENSG00000082175, ENSG00000141736","EFO_0005537","ESR1 PROTEIN EXPRESSION NEGATIVE MISSING PGR PROTEIN EXPRESSION NEGATIVE MISSING ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"66","TAMOXIFEN",NA,"BREAST CANCER","SPP1,
OPN","gene expression, protein expression","positive, positive","OR","patients","31996744","Evaluation of SPP1/osteopontin expression as predictor of recurrence in tamoxifen treated breast cancer.","OPN protein expression was not associated with risk of recurrence or with SPP1-gene expression, suggesting SPP1 mRNA a stronger prognostic marker candidate compared to tumor tissue OPN protein.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31996744",NA,"DB00675","2733526","ENSG00000118785, ENSG00000118785","MONDO_0007254","SPP1 GENE EXPRESSION POSITIVE OR OPN PROTEIN EXPRESSION POSITIVE","pass"
"67","TRASTUZUMAB",NA,"BREAST CANCER CELL LINE MODEL","BRAF,KRAS,
PIK3CA","mutation,mutation,mutation","positive, positive, positive","MISSING, MISSING, MISSING","cell line","31983154","BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model.","BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31983154",NA,"DB00072","3001322","ENSG00000157764, ENSG00000133703, ENSG00000121879","MONDO_0007254","failed","failed term"
"68","ANTHRACYCLINES, TRASTUZUMAB",NA,"BREAST CANCER","hs-cTnT
NT-proBNP,
myeloperoxidase
placental growth factor, growth differentiation factor 15","protein expression,   protein expression, protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive, positive, positive","AND, AND, AND, AND","patients","31959034","Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.","Conclusions Cardiovascular biomarkers may play an important role in CTRCD risk prediction in patients with breast cancer who receive cardiotoxic cancer therapy, particularly in those treated with sequential anthracycline and trastuzumab therapy. ","https://www.ncbi.nlm.nih.gov/pubmed/?term=31959034",NA,"NA,DB00072","NA, 3001322","NA, NA, ENSG00000130513","MONDO_0007254","failed","failed drug,failed biomarker,failed term"
"69","DOXORUBICIN",NA,"BREAST CANCER","Twist 1","gene expression","positive",NA,"patients","31942413","Gene Expression as a Biomarker for Predicting Primary Doxorubicin Resistance in Breast Cancer.","gene expression as a biomarker for predicting the response of breast tumors to chemo-therapeutic agent doxorubicin.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31942413",NA,"DB00997","443939","NA","MONDO_0007254","TWIST 1 GENE EXPRESSION POSITIVE","failed biomarker"
"70","TRASTUZUMAB",NA,"HER2-POSITIVE METASTATIC BREAST CANCER","ERBB2, CA15.3,
CEA","protein expression, protein expression, protein expression","positive, positive, positive,","AND, AND","patients","31910438","An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.","Regular measurement of sHER2, CA15.3, and CEA levels is useful for predicting the therapeutic response and for monitoring HER2-targeted therapy in patients with HER2-positive metastatic breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31910438",NA,"DB00072","3001322","ENSG00000141736, NA, ENSG00000105388","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND CA15.3 PROTEIN EXPRESSION POSITIVE AND CEA PROTEIN EXPRESSION POSITIVE","pass"
"71","NA",NA,"HER2-NEGATIVE BREAST CANCER","ERBB2","protein expression","negative","OR","patients","31907749","Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.","two commercial breast cancer prognostic scores were significant predictors of response to NaCT.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31907749",NA,"NA","56956252","ENSG00000141736","MONDO_0007254","failed","failed term"
"72","FAK INHIBITORS",NA,"TRIPLE-NEGATIVE BREAST CANCER","FAK","protein expression","positive",NA,"patients","31905966","Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.","Our findings provide new insights into the cytotoxic effect of CIK cell therapy in TNBC treatment, and show that CIK cell therapy combined with FAK inhibitors may be a novel therapeutic strategy for patients with TNBC.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31905966",NA,"NA","NA","ENSG00000169398","EFO_0005537","FAK PROTEIN EXPRESSION POSITIVE","failed drug"
"73","CHOLECALCIFEROL, TAMOXIFEN",NA,"BREAST CANCER","VEGF-A, Ang-2,
Hif-1, high-sensitivity C-reactive protein ","protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive","AND, AND, AND","patients","31901710","Effects of cholecalciferol supplementation on serum angiogenic biomarkers in breast cancer patients treated with tamoxifen: A controlled randomized clinical trial.","Cholecalciferol supplementation achieved sufficient efficacy among patients with BC taking tamoxifen and could be effective in the reduction of angiogenic biomarkers particularly dependent on the infiltration status of the tumor to vessels. ","https://www.ncbi.nlm.nih.gov/pubmed/?term=31901710",NA,"DB00169,DB00675","5280795, 2733526","ENSG00000112715, ENSG00000091879, ENSG00000168209, NA","MONDO_0007254","VEGF-A PROTEIN EXPRESSION POSITIVE AND ANG-2 PROTEIN EXPRESSION POSITIVE AND HIF-1 PROTEIN EXPRESSION POSITIVE AND HIGH-SENSITIVITY C-REACTIVE PROTEIN PROTEIN EXPRESSION POSITIVE","pass"
"74","MISSING",NA,"BREAST CANCER","missing",NA,NA,NA,NA,"31897326","Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy","This review summarizes and compares various predictive and prognostic indicators for patients who have received neoadjuvant chemotherapy, and analyzes their efficacy in different breast cancer subtypes.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31897326",NA,"NA","NA","ENSG00000170873","MONDO_0007254","MISSING NA NA","failed drug"
"75","MISSING",NA,"EARLY STAGE BREAST CANCER","missing",NA,NA,NA,NA,"31869667","Imperfect biomarkers for adjuvant chemotherapy in early stage breast cancer with good prognosis","To evaluate the ways in which the diffusion of biomarkers questions the autonomy of clinicians, we consider the case of chemotherapy prescription to women with early stage breast cancer and a good prognosis. ","https://www.ncbi.nlm.nih.gov/pubmed/?term=31869667",NA,"NA","NA","ENSG00000170873","MONDO_0007254","MISSING NA NA","failed drug"
"76","TRASTUZUMAB",NA,"HER 2+ AND
HER2-  BREAST CANCER","ERBB2","protein expression","positive/negative",NA,"patients","31867841","Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling","In summary, ctDNA monitoring, particularly longitudinal analyses, provides valuable insights into the assessment of targeted therapy efficacy and gene alterations underlying trastuzumab resistance and chemotherapy resistance in HER2+ and HER2- BC patients, respectively.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31867841",NA,"DB00072","3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"77","PI3KI, ANTI-HER2 AGENTS, CHEMOTHERAPY, CDK4/6 INHIBITORS, MTOR INHIBITORS",NA,"ESTROGEN RECEPTOR-POSITIVE BREAST CANCER","PIK3CA","protein expression,
protein expression","positive",NA,"patients","31859350","Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.","In this review, we discuss biomarkers of response and resistance to PI3K inhibitors (PI3Ki) in estrogen receptor-positive breast cancer","https://www.ncbi.nlm.nih.gov/pubmed/?term=31859350",NA,"NA,NA,NA,NA,NA","NA, NA, 94994, NA, NA","ENSG00000121879","EFO_1000649","failed","failed drug,failed term"
"78","MISSING",NA,"METASTATIC TRIPLE-NEGATIVE BREAST CANCER","CTCs","protein expression, protein expression,
protein expression, others","negative, negative,  negative, negative",NA,"patients","31849532","First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial.","Efficacy outcomes trended positively with chemotherapy-induced elimination of CTCs, suggesting that CTC clearance may predict the chemosensitivity of mTNBC tumors.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31849532",NA,"NA","NA","NA","MONDO_0007254","failed","failed drug,failed biomarker,failed term"
"79","MISSING",NA,"HR+ HER2- EARLY INVASIVE BREAST CANCER","ESR1, PGR, ERBB2, uPA/PAI-1, OncotypeDX®, MammaPrint®, PAM50,  EndoPredict®","protein expression, protein expression,
protein expression, missing, others, others,others,others","positive, positive, negative, positive, positive, positive, positive, positive","AND, AND, AND, AND","others","31849525","Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?","Even though data currently available confirm the clinical validity of these biomarkers, there is a lack of data regarding clinical utility for most of them. ","https://www.ncbi.nlm.nih.gov/pubmed/?term=31849525",NA,"NA","NA","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000142871, NA, NA, NA, NA","MONDO_0007254","failed","failed drug,failed term"
"80","BAY 1125976",NA,"BREAST CANCER","AKT","mutation","positive",NA,"patients","31835495","Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.","Genetic analyses revealed additional mutations that could promote tumor cell growth despite the inhibition of AKT1/2.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31835495",NA,"NA","70817911","ENSG00000166971","MONDO_0007254","AKT MUTATION POSITIVE","pass"
"81","HDAC8 INHIBITOR",NA,"BREAST CANCER CELLS","HDAC8","protein expression","positive",NA,"cell line","31817161","Induction of Apoptosis and Autophagy in Breast Cancer Cells by a Novel HDAC8 Inhibitor","These data suggest the translational potential of HMC to be developed into a potential therapeutic agent for breast cancer therapy.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31817161",NA,"NA","NA","ENSG00000147099","MONDO_0007254","HDAC8 PROTEIN EXPRESSION POSITIVE","failed drug"
"82","PALBOCICLIB, RIBOCICLIB, ABEMACICLIB","CDK4/6","BREAST CANCER","CDK4, CDK6","protein expression, protein expression","positive, positive","AND","patients","31777590","Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future.","The CDK4/6 inhibitors application after the support of preclinic and clinic data will be helpful to provide other alternatively suitable strategies for different types of breast cancer patients.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31777590",NA,"DB09073,DB11730,DB12001","11478676, 44631912, 46220502","ENSG00000135446, ENSG00000105810","MONDO_0007254","CDK4 PROTEIN EXPRESSION POSITIVE AND CDK6 PROTEIN EXPRESSION POSITIVE","pass"
"83","NAPABUCASIN, TAMOXIFEN",NA,"ESTROGEN RECEPTOR-POSITIVE (ER+) BREAST CANCER","ESR1","protein expression","positive",NA,"cell line","31760402","Napabucasin Attenuates Resistance of Breast Cancer Cells to Tamoxifen by Reducing Stem Cell-Like Properties.","NP might be used as an adjuvant therapy for ER+ BC patients with TAM resistance.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31760402",NA,"DB12155,DB00675","10331844, 2733526","ENSG00000091831","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"84","Β-BLOCKADE, PROPRANOLOL",NA,"BREAST CANCER","Snail/Slug, NF-Κb, AP-1","missing, missing, missing","positive,positive,positive","AND","patients","31754048","Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial.","These results show that β-blockade reduces biomarkers associated with metastatic potential, and support the need for larger phase III clinical trials powered to detect the impact of β-blockade on cancer recurrence and survival.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31754048",NA,"NA,DB00571","NA, 62882","NA, NA, ENSG00000177606","MONDO_0007254","failed","failed drug,failed biomarker,failed term"
"85","PEMBROLIZUMAB",NA,"METASTATIC TRIPLE-NEGATIVE BREAST CANCER","ESR1, PGR, ERBB2, PD-L1","protein expression, protein expression,  protein expression, protein expression","negative, negative, negative, positive","MISSING, MISSING, MISSING","patients","31747077","A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.","The combination of pembrolizumab and RT was found to be safe and demonstrated encouraging activity in patients with poor-prognosis, metastatic, triple-negative breast cancer who were unselected for programmed death-ligand 1 expression.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31747077",NA,"DB09037","NA","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000120217","MONDO_0007254","ESR1 PROTEIN EXPRESSION NEGATIVE MISSING PGR PROTEIN EXPRESSION NEGATIVE MISSING ERBB2 PROTEIN EXPRESSION NEGATIVE MISSING PD-L1 PROTEIN EXPRESSION POSITIVE","pass"
"86","PSAMMAPLIN A ANALOG",NA,"TRIPLE-NEGATIVE BREAST CANCER","H3K79,DOT1L
","protein expression, protein expression,  protein expression, methylation","positive, positive","AND","mouse","31720371","Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.","We report here a new template of DOT1L inhibitor and suggest that targeting DOT1L-mediated H3K79 methylation by a novel PsA analog may be a promising strategy for the treatment of metastatic breast cancer patients.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31720371",NA,"NA","NA","NA, ENSG00000104885","EFO_0005537","failed","failed drug,failed biomarker,failed term"
"87","DOXORUBICIN, CYCLOPHOSPHAMIDE",NA,"TRIPLE-NEGATIVE BREAST CANCER","DDIR,sTILs","protein expression, protein expression,  protein expression, gene expression","positive, positive","AND","patients","31657982","Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.","The prognostic role of sTILs and DDIR in early-stage TNBC was confirmed.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31657982",NA,"DB00997,DB00531","443939, 2907","NA, NA","EFO_0005537","failed","failed biomarker,failed term"
"88","NA",NA,"TRIPLE-NEGATIVE BREAST CANCER","ESR1, PGR, ERBB2","protein expression, protein expression,  protein expression,","negative, negative, negative","MISSING, MISSING, MISSING","cell line","31655920","Molecular determinants of drug response in TNBC cell lines.","These findings demonstrate an integrated method to identify biomarkers of drug efficacy in TNBC where DNA predictions correlate poorly with drug response.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31655920",NA,"NA","56956252","ENSG00000091831, ENSG00000082175, ENSG00000141736","EFO_0005537","failed","failed term"
"89","MISSING",NA,"BREAST CANCER","GRP 78, 
BIK, NBK","protein expression, protein expression, protein expression","positive, positive, positive","AND, AND","patients","31635499","Correlation of the protein expression of GRP78 and BIK/NBK with prognostic markers in patients with breast cancer and neoadjuvant chemotherapy.","There is a potential prognostic value of GRP78 and BIK/NBK in the pathological response that merits further study addressing their interaction with other proteins","https://www.ncbi.nlm.nih.gov/pubmed/?term=31635499",NA,"NA","NA","NA, ENSG00000100290, ENSG00000100290","MONDO_0007254","GRP 78 PROTEIN EXPRESSION POSITIVE AND BIK PROTEIN EXPRESSION POSITIVE AND NBK PROTEIN EXPRESSION POSITIVE","failed drug,failed biomarker"
"90","MISSING",NA,"BREAST CANCER","microbiota","others","positive",NA,"patients","31628201","Neoadjuvant Chemotherapy Shifts Breast Tumor Microbiota Populations to Regulate Drug Responsiveness and the Development of Metastasis.","Breast tumor microbiota are modified by therapy and affects molecular signaling.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31628201",NA,"NA","NA","NA","MONDO_0007254","MICROBIOTA OTHERS POSITIVE","failed drug,failed biomarker"
"91","MISSING",NA,"HER2- EARLY BREAST CANCER","ESR1, PGR, ERBB2, FGFR1, MAP3K1","protein expression, protein expression, protein expression, amplification, 
mutation","positive, positive, negative, positive, positive","AND","patients","31620934","Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.","In axillary node-positive, HR+, and HER2- early BC, amplifications of FGFR1 gene were strongly associated with increased risk for distant disease, while mutations of MAP3K1 gene were significantly associated with decreased risk.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31620934",NA,"NA","NA","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000077782, ENSG00000095015","MONDO_0007254","failed","failed drug,failed term"
"92","TRASTUZUMAB",NA,"HER2-POSITIVE BREAST CANCER","PAGES-HBC","protein expression, protein expression","positive, positive",NA,"patients","31618954","PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer.","We conclude that PAGES-HBC could be further developed as a prognostic predictor of trastuzumab response in HER2+ breast cancer patients and be potentially used as an alternative biomarker for anti-PD-1 therapy trials.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31618954",NA,"DB00072","3001322","NA","EFO_1000294","failed","failed biomarker,failed term"
"93","ATEZOLIZUMAB, NABPACLITAXEL",NA,"METASTATIC TRIPLE-NEGATIVE BREAST CANCER","ESR1, PGR, ERBB2, PD-L1","protein expression, protein expression, protein expression, protein expression","negative, negative, negative, positive","MISSING, MISSING, MISSING",NA,"31612573","Immunotherapy: The end of the ""dark age"" for metastatic triple-negative breast cancer?","With the demonstration of a statistically significant improvement of progression-free survival with the addition of atezolizumab to nab-paclitaxel in the first-line treatment of mTNBC, accompanied by a substantial overall survival benefit in the PD-L1-positive subgroup. ","https://www.ncbi.nlm.nih.gov/pubmed/?term=31612573",NA,"DB11595,NA","NA, NA","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000120217","MONDO_0007254","ESR1 PROTEIN EXPRESSION NEGATIVE MISSING PGR PROTEIN EXPRESSION NEGATIVE MISSING ERBB2 PROTEIN EXPRESSION NEGATIVE MISSING PD-L1 PROTEIN EXPRESSION POSITIVE","pass"
"94","CDK 4/6 INHIBITORS",NA,"HR+MBC","ESR1, PGR","protein expression, protein expression","positive, positive","MISSING",NA,"31610139","A clinical evaluation of treatments that target cell cycle machinery in breast cancer.","In the Her2 positive subtype, the triple combination of anti Her2 therapies with CDK4/6 inhibitors and endocrine therapy seems to be a promising chemotherapy free approach.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31610139",NA,"NA","NA","ENSG00000091831, ENSG00000082175","NA","ESR1 PROTEIN EXPRESSION POSITIVE MISSING PGR PROTEIN EXPRESSION POSITIVE","failed drug,failed disease"
"95","MISSING",NA,"METASTATIC BREAST CANCER","TK1, CDK9, CDK4","gene expression,   gene expression, gene expression","positive, positive, positive","AND, AND","patients","31346846","Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.","The present study demonstrates that, in plasma-derived exosomes, high baseline CDK4 mRNA levels are associated with response to palbociclib plus hormonal therapy, while the increase in TK1 and CDK9 mRNA copies/ml is associated with clinical resistance.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31346846",NA,"NA","NA","ENSG00000167900, ENSG00000136807, ENSG00000135446","EFO_1000984","TK1 GENE EXPRESSION POSITIVE AND CDK9 GENE EXPRESSION POSITIVE AND CDK4 GENE EXPRESSION POSITIVE","failed drug"
"96","MISSING",NA,"METASTATIC BREAST CANCER","MTHFR, TYMS, MTHFR, MTHFR","polymorphism, polymorphism, polymorphism, polymorphism","positive, positive, positive, positive","AND, AND, AND","patients","31601265","Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.","We have identified four potentially useful pharmacogenetic markers, TYMS rs2606241, TYMS rs2853741, MTHFR rs3737964, and MTHFR rs4846048 to predict capecitabine-induced HFS in MBC patients.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31601265",NA,"NA","NA","ENSG00000177000, ENSG00000176890","EFO_1000984","failed","failed drug,failed term"
"97","MISSING",NA,"INVASIVE BREAST CANCER","claudins,cadherin","protein expression,   protein expression","positive, positive","AND, AND","patients","31572543","Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer.","These findings indicate that claudins-1 and -3 serve a role in the response of BC to chemotherapy.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31572543",NA,"NA","NA","NA, ENSG00000039068","EFO_1000307","failed","failed drug,failed biomarker,failed term"
"98","PAN-PI3K INHIBITOR, BUPARLISIB, LETROZOLE",NA,"ER+ METASTATIC BREAST CANCER","ER, PIK3CA, MAP3K1","protein expression, mutation, mutation","positive, positive, positive","AND, AND, AND","patients","31552290","PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.","Mutations in MAP3K1 in ER+ breast cancer may be associated with clinical benefit from combined inhibition of PI3K and ER","https://www.ncbi.nlm.nih.gov/pubmed/?term=31552290",NA,"NA,DB11666,DB01006","NA, 16654980, 3902","ENSG00000091831, ENSG00000121879, ENSG00000095015","MONDO_0007254","failed","failed drug,failed term"
"99","NIRAPARIB, PEMBROLIZUMAB",NA,"ADVANCED TRIPLE-NEGATIVE BREAST CANCER","BRCA","mutation","positive",NA,"patients","31194225","Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.","Combination niraparib plus pembrolizumab provides promising antitumor activity in patients with advanced or metastatic TNBC, with numerically higher response rates in those with tumor BRCA mutations.","https://www.ncbi.nlm.nih.gov/pubmed/31194225",NA,"DB11793,DB09037","24958200, NA","ENSG00000012048","MONDO_0007254","BRCA MUTATION POSITIVE","pass"
"100","NA",NA,"BREAST CANCER","Ki-67, p53,BCL-2","protein expression,   protein expression, protein expression","positive,positive,positive","AND,AND","patients","31289309","Ki-67, p53 and BCL-2 Expressions and their Association with Clinical Histopathology of Breast Cancer among Women in Tanzania.","Multinomial linear regression showed higher possibility for association between high expression of Ki-67, low expression of p53 and high expression of BCL-2 with age, grade, stage and tumor (T) stage 
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31289309","No drug was mentioned in the abstract.","NA","56956252","ENSG00000148773, ENSG00000141510, ENSG00000171791","MONDO_0007254","KI-67 PROTEIN EXPRESSION POSITIVE AND P53 PROTEIN EXPRESSION POSITIVE AND BCL-2 PROTEIN EXPRESSION POSITIVE","pass"
"101","NA",NA,"BREAST CANCER","EphB1,EphB2,EphB3, 
EphB4, EphB6","protein expression, protein expression, protein expression, protein expression, protein expression","positive,
positive, positive, positive, positive","OR,OR,OR,OR","patients","31289549","Prognostic value of ephrin B receptors in breast cancer: An online survivalanalysis using the microarray data of 3,554 patients.","The results of the present suggested that EphB receptors may be useful as prognostic biomarkers of breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31289549","No drug was mentioned in the abstract.","NA","56956252","ENSG00000154928, ENSG00000133216, ENSG00000182580, ENSG00000196411, ENSG00000106123","MONDO_0007254","EPHB1 PROTEIN EXPRESSION POSITIVE OR EPHB2 PROTEIN EXPRESSION POSITIVE OR EPHB3 PROTEIN EXPRESSION POSITIVE OR EPHB4 PROTEIN EXPRESSION POSITIVE OR EPHB6 PROTEIN EXPRESSION POSITIVE","pass"
"102","NA",NA,"BREAST CANCER","CD 274, IL8,TGFβ1, MIF,
 VEGFA","protein expression, protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive, positive","OR,OR,OR,OR","basal-like breast cancer cell lines and tissue samples.","31293831","Screening of immunosuppressive factors for biomarkers of breast cancer malignancy phenotypes and subtype-specific targeted therapy.","IL8,TGFβ1, MIF and VEGFA could be used as biomarkers for breast cancer prognosis.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31293831","No drug was mentioned in the abstract.","NA","56956252","NA, ENSG00000164850, NA, ENSG00000240972, ENSG00000112715","MONDO_0007254","CD 274 PROTEIN EXPRESSION POSITIVE OR IL8 PROTEIN EXPRESSION POSITIVE OR TGFΒ1 PROTEIN EXPRESSION POSITIVE OR MIF PROTEIN EXPRESSION POSITIVE OR VEGFA PROTEIN EXPRESSION POSITIVE","failed biomarker"
"103","CARBOPLATIN, CISPLATIN, OXALIPLATIN",NA,"BREAST CANCER","BRCA1, BRCA2, p53, p63, p73","gene mutation, gene mutation, protein expression, protein expression, protein expression","positive,positive, positive, positive, positive","OR,AND, OR, OR","patients","31295913","Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors.","The association between BRCA1/2 gene mutations and platinum sensitivity has been largely described.Moreover, p53 and its family members (p63 and p73) might also be used as predictors of platinum response.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31295913","This is a review. Biomarker relationhips were not clearly stated in the abstract.","DB00958,DB00515,DB00526","56840877, 135804801, 71301229","ENSG00000012048, ENSG00000139618, ENSG00000141510, ENSG00000073282, ENSG00000078900","MONDO_0007254","BRCA1 GENE MUTATION POSITIVE OR BRCA2 GENE MUTATION POSITIVE AND P53 PROTEIN EXPRESSION POSITIVE OR P63 PROTEIN EXPRESSION POSITIVE OR P73 PROTEIN EXPRESSION POSITIVE","pass"
"104","NA",NA,"METASTATIC BREAST CANCER","PIK3CA","gene mutation","positive",NA,"patients","31297647","PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.","PIK3CA gene mutation is one of the most frequent events in mBC and is associated with HT resistance.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31297647","No drug was mentioned in the abstract.","NA","56956252","ENSG00000121879","EFO_1000984","PIK3CA GENE MUTATION POSITIVE","pass"
"105","NA",NA,"METASTATIC BREAST CANCER","miR-106b","gene expression","positive",NA,"patients","31300482","Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.","The phenotypic assemblies of CTC incorporating miR-106b show enhanced
prognostic accuracy of overall survival in patients with MBC
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31300482","No drug was mentioned in the abstract.","NA","56956252","NA","EFO_1000984","MIR-106B GENE EXPRESSION POSITIVE","failed biomarker"
"106","ANTHRACYCLINE",NA,"BREAST CANCER","TOP2α, ERBB2","gene expression,  gene expression","positive, positive","AND","feline mammary tumors","31301170","Assessment of ERBB2 and TOP2α gene status and expression profile in feline mammary tumors: findings and guidelines.","Results showed that ERBB2 and TOP2α gene status are highly correlated (r=0.87, p<0.0001, n=25), with few tumor samples presenting amplification.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31301170","Drug names are mentioned in the abstract.","NA","NA","NA, ENSG00000141736","MONDO_0007254","TOP2Α GENE EXPRESSION POSITIVE AND ERBB2 GENE EXPRESSION POSITIVE","failed drug,failed biomarker"
"107","NA",NA,"BREAST CANCER",NA,NA,NA,NA,NA,"31306700","Evaluating the glycophenotype on breast cancer tissues with quantum dots-Cramoll lectin conjugates.",NA,"https://www.ncbi.nlm.nih.gov/pubmed/?term=31306700","No drug and biomarker was mentioned in the abstract.","NA","56956252","ENSG00000183023","MONDO_0007254","NA NA NA","no biomarker"
"108","NA",NA,"BREAST CANCER","ESR1, PGR, ERBB2, BRCA1, BRCA2
CLDN3, CK5, CK14","protein expression, protein expression, protein expression, mutation, mutation,  protein expression, protein expression, protein expression","negative, negative, negative, positive, positive, positive, positive, positive","missing,missing,missing,AND/OR,AND/OR, AND/OR,AND/OR","patients","31307407","Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.","Our data suggests that CLDN3, CK5, and CK14 in combination with ER, PR and HER2 are associated with BRCA1 mutation status
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31307407","No drug was mentioned in the abstract,   complicated loical relationship.","NA","56956252","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000012048, NA, NA, NA","MONDO_0007254","failed","failed term"
"109","NA",NA,"BREAST CANCER","ERBB2","protein expression","positive",NA,"patients","31307703","Femtomolar electroanalysis of a breast cancer biomarker HER-2/neu protein in human serum by the cellulase-linked sandwich assay on magnetic beads.","In cancer diagnostics, specific analysis of blood-circulating proteins biomarkers of cancer is often complicated both by their inherently low concentrations and by strong interference from serum/blood proteins.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31307703","No drug was mentioned in the abstract.","NA","56956252","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"110","NA",NA,"BREAST CANCER","Let-7a-5p,miRNA-21-5p","gene expression, gene expression","positive, positive","OR","patients","31308028","Clinical Significance of let-7a-5p and miR-21-5p in Patients with Breast Cancer.","Reduced expression of Let-7a-5p and miR-21-5p levels is of little
value for early diagnosis of breast cancer; however reduced expression of Let-7a-5p and miRNA-21-5p may serve as non-invasive biomarkers for the diagnosis  of breast cancer metastasis, and combination of these markers with CEA and CA15-3 can help to distinguish benign breast lesions from breast cancer
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31308028","No drug was mentioned in the abstract.","NA","56956252","NA, NA","MONDO_0007254","LET-7A-5P GENE EXPRESSION POSITIVE OR MIRNA-21-5P GENE EXPRESSION POSITIVE","failed biomarker"
"111","NA",NA,"BREAST CANCER","SARNP(Hcc-1 and CIP29)","protein expression","positive",NA,"mice","31313837","SARNP, a participant in mRNA splicing and export, negatively regulates E-cadherin expression via interaction with pinin.","The SARNP overexpression induced the proliferation of
MCF7 cells, whereas its knockdown induced E-cadherin expression and downregulated
vimentin and N-cadherin expressions in SK-BR-3 and MDA-MB-231 cells.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31313837","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","SARNP(HCC-1 AND CIP29) PROTEIN EXPRESSION POSITIVE","failed biomarker"
"112","NA",NA,"BREAST CANCER",NA,NA,NA,NA,NA,"31315912","An Environmental Scan of Biopsychosocial and Clinical Variables in Cohort Studies.",NA,"https://www.ncbi.nlm.nih.gov/pubmed/?term=31315912",NA,"NA","56956252","ENSG00000183023","MONDO_0007254","NA NA NA","no biomarker"
"113","TRASTUZUMAB, TAXANE",NA,"BREAST CANCER","ERBB2","protein expression","positive",NA,"patients","31318460","Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.","In the phase 3 MARIANNE trial, trastuzumab emtansine (T-DM1) with or  without pertuzumab showed noninferior progression-free survival and better
tolerability than trastuzumab plus a taxane (HT) for the first-line treatment of  human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31318460","Drug names are mentioned in the abstract.","DB00072,NA","3001322, 9548828","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"114","ESTROGEN, PROGESTERONE","human epidermal growth factor 2 receptors","BREAST CANCER","ESR1, PGR,ERBB2","protein expression, protein expression, protein expression","positive, positive, positive","OR,OR","patients","31319941","Evaluate Cutpoints: Adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator.","Example algorithm cutp showed that lowered expression of ESR1 and ERBB2 was more favorable , whereas heightened PGR expression was correlated with better prognosis.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31319941","Drug names are mentioned in the abstract.","NA,DB00396","448537, 5994","ENSG00000091831, ENSG00000082175, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE OR ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"115","NA","KYNU","BREAST CANCER","Kynureninase(KYNU), ESR1, PGR, ERBB2, E-cad, Ki-67","gene expression, protein expression, protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive, positive, positive","AND,AND,AN,/AND,AND","patients","31332944","A novel role of kynureninase in the growth control of breast cancer cells and its relationships with breast cancer.","Kynureninase may function as a tumour suppressor in BC.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31332944","No drug was mentioned in the abstract.","NA","56956252","NA, ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000039068, ENSG00000148773","MONDO_0007254","KYNURENINASE(KYNU) GENE EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AN ERBB2 PROTEIN EXPRESSION POSITIVE /AND E-CAD PROTEIN EXPRESSION POSITIVE AND KI-67 PROTEIN EXPRESSION POSITIVE","failed biomarker"
"116","NA",NA,"HEMATOLOGIC
MALIGNANCIES AND BREAST CANCER.","NLR,MLR","others","positive, positive","OR","patients","31339198","Association of preoperative monocyte-to-lymphocyte and neutrophil-to-lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (US-NETSG)","In addition to established tumor-specific factors, preoperative NLR
levels can serve as a valuable biomarker that can be used as a predictor of OS and RFS after resection of PNETs.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31339198","No drug was mentioned in the abstract.","NA","56956252","ENSG00000179583, ENSG00000151623","MONDO_0007254","failed","failed term"
"117","NA",NA,"T1-3, N0 BREAST CANCER","ALDH1A3, CD44+/CD24-, ITGA6,PROCR
","protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive","OR,OR,OR","BCSCs","31340763","A multiple breast cancer stem cell model to predict recurrence of T1-3, N0 breast cancer.","The RRS model can be applied to predict the relapse risk in early
stage breast cancer. As such, high RRS score ER-positive patients do not benefit  from hormonal therapy treatment.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31340763","No drug was mentioned in the abstract.","NA","56956252","ENSG00000184254, NA, ENSG00000091409, ENSG00000101000","MONDO_0007254","ALDH1A3 PROTEIN EXPRESSION POSITIVE OR CD44+/CD24- PROTEIN EXPRESSION POSITIVE OR ITGA6 PROTEIN EXPRESSION POSITIVE OR PROCR PROTEIN EXPRESSION POSITIVE","pass"
"118","NA",NA,"BREAST CANCER","ER,PR, ERBB2","protein expression, protein expression, protein expression","positive, positive, positive","OR,OR","patients","31348505","Artificial Intelligence Algorithms to Assess Hormonal Status From Tissue Microarrays in Patients With Breast Cancer.","Morphological-based molecular profiling could be used as a general
approach for mass-scale molecular profiling based on digitized H&E-stained images, allowing quick, accurate, and inexpensive methods for simultaneous profiling of multiple biomarkers in cancer tissues.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31348505","No drug was mentioned in the abstract.","NA","56956252","ENSG00000091831, ENSG00000134551, ENSG00000141736","MONDO_0007254","ER PROTEIN EXPRESSION POSITIVE OR PR PROTEIN EXPRESSION POSITIVE OR ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"119","VITAMIN D",NA,"BREAST CANCER","FokI, BsmI, ApaI,TaqI,TAC","polymorphism, polymorphism, polymorphism, polymorphism, protein expression","positive, positive, positive,positive, positive","OR,OR,OR,OR","patients and mice","31350967","Genetic Variations in VDR could Modulate the Efficacy of Vitamin D3 Supplementation on Inflammatory Markers and Total Antioxidant Capacity among Breast Cancer Women: A Randomized Double Blind Controlled Trial.","Supplementation with a vitamin D3 increased the TAC in breast cancer
women, although it had no effect on inflammatory markers. Serum TAC in the TT/Tt, Ff were more responsive to vitamin D supplement compared with those with the
FF/ff and tt genotypes.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31350967","Drug names are mentioned in the abstract.","DB11094","5280795","NA, NA, NA, NA, ENSG00000134460","MONDO_0007254","FOKI POLYMORPHISM POSITIVE OR BSMI POLYMORPHISM POSITIVE OR APAI POLYMORPHISM POSITIVE OR TAQI POLYMORPHISM POSITIVE OR TAC PROTEIN EXPRESSION POSITIVE","failed biomarker"
"120","NA",NA,"BREAST CANCER","ESR1","protein expression","positive/neagtive",NA,"patients and mice","31351853","Self-reported residential pesticide use and survival after breast cancer.","Contrary to our hypothesis, lifetime residential use of lawn and garden pesticides, but not all combined or nuisance-pest pesticides, was
inversely associated with all-cause mortality after breast cancer.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31351853",NA,"NA","56956252","ENSG00000091831","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE/NEAGTIVE","pass"
"121","NA",NA,"BREAST CANCER","Ki-67, ERBB2, H-MRS","protein expression, protein expression, others","positive, positive, positive","OR,OR","patients","31356383","Breast Magnetic Resonance Spectroscopy at 3 T in Biopsy-Proven Breast Cancers: Does Choline Peak Correlate With Prognostic Factors?","Our study confirms that 3 T breast H-MRS can be a valid additional tool to obtain further information about breast cancer biology and to predict tumor aggressiveness
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31356383","No drug was mentioned in the abstract.","NA","56956252","ENSG00000148773, ENSG00000141736, NA","MONDO_0007254","KI-67 PROTEIN EXPRESSION POSITIVE OR ERBB2 PROTEIN EXPRESSION POSITIVE OR H-MRS OTHERS POSITIVE","pass"
"122","NA",NA,"BREAST CANCER","uPA,uPAR,PAI-1,PAI-2","protein expression, protein expression, protein expression, protein expression,","positive, positive, positive, positive","AND,AND,AND","patients","31359505","Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.","ER and PR protein of primary breast 
cancers combined with analyses of uPA, uPAR, and PAI-1 protein content improves assessment of clinical outcomes.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31359505","No drug was mentioned in the abstract.","NA","56956252","ENSG00000122861, ENSG00000011422, ENSG00000106366, ENSG00000197632","MONDO_0007254","UPA PROTEIN EXPRESSION POSITIVE AND UPAR PROTEIN EXPRESSION POSITIVE AND PAI-1 PROTEIN EXPRESSION POSITIVE AND PAI-2 PROTEIN EXPRESSION POSITIVE","pass"
"123","NA",NA,"BREAST CANCER","cfDNA, CIN","gene expression, gene expression","positive, positive","OR","patients","31364001","Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.","cfDNA CIN yields a higher accuracy in monitoring breast cancer recurrence compared to traditional biomarkers (CA15-3 and CEA), especially for biomarker-negative patients.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31364001","No drug was mentioned in the abstract.","NA","56956252","NA, ENSG00000241360","MONDO_0007254","CFDNA GENE EXPRESSION POSITIVE OR CIN GENE EXPRESSION POSITIVE","failed biomarker"
"124","NA",NA,"BREAST CANCER","ERBB2,ESR1,PGR","protein expression, protein expression, protein expression","positive, positive, positive","AND,AND","patients","31373514","Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2/neu Evaluation.","Evaluation of estrogen receptor (ER), progesterone receptor (PR), and HER2/neu (HER2) biomarkers is standard of care for all cases of newly diagnosed invasive, recurrent, and metastatic breast cancer. 
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31373514","No drug was mentioned in the abstract.","NA","56956252","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"125","NA",NA,"BREAST CANCER","TXN, ANXA 2,
LOXL2, TPM4, 
TPRN, ADCY6, 
TUBA1C,CMIP","gene expression, gene expression, gene expression, gene expression, gene expression,gene expression","positive,positive, positive,positive, positive,positive, positive,positive","AND,
AND,
AND,
AND","patients","31382519","Identification of Prognostic Candidate Genes in Breast Cancer by Integrated Bioinformatic Analysis.","In the present study, eight candidate biomarkers were identified for
further basic and advanced understanding of the molecular pathogenesis of breast cancer by using co-expression network analysis.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31382519","No drug was mentioned in the abstract.","NA","56956252","ENSG00000136810, NA, ENSG00000134013, ENSG00000167460, ENSG00000176058, ENSG00000174233, ENSG00000167553, ENSG00000153815","MONDO_0007254","failed","failed term"
"126","NA",NA,"BREAST CANCER","ESR1,ERBB2","protein expression, protein expression","positive, positive","AND","patients","31385051","Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk.","The ADC difference value derived from whole-lesion histogram analysis might serve as a quantitative DWI biomarker of the recurrence risk in women with ER-positive, HER2-negative, node-negative invasive breast cancer.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31385051","No drug was mentioned in the abstract.","NA","56956252","ENSG00000091831, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"127","NA",NA,"BREAST CANCER","HR, HER2","protein expression, protein expression, protein expression","positive, positive","AND","patients","31386016","Biological subtypes and survival outcomes in breast cancer patients with brain metastases in the targeted therapy era.","Comparing all breast cancer subgroups we noticed that HR and HER2 are the most significant biomarkers in brain metastasis behavior. 
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31386016","No drug was mentioned in the abstract.","NA","56956252","ENSG00000168453, ENSG00000141736","MONDO_0007254","failed","failed term"
"128","NA",NA,"BREAST CANCER","FOXM1","protein expression","positive",NA,"21T series cell lines","31391072","Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer.","Deciphering the molecular mechanisms during BC progression is therefore crucial to prevent over- 
or under-treatment.
","https://www.ncbi.nlm.nih.gov/pubmed/?term= 31391072","Drug names are mentioned in the abstract.","NA","56956252","ENSG00000111206","MONDO_0007254","FOXM1 PROTEIN EXPRESSION POSITIVE","pass"
"129","NA",NA,"BREAST CANCER","miR-200","gene expression","positive",NA,"patients","31394177","Integrative data mining and meta-analysis to investigate the prognostic role of microRNA-200 family in various human malignant neoplasms: A consideration on heterogeneity.","Our results convincingly demonstrated that the miR-200 family could  serve as a prognostic biomarker for cancers mentioned above and has potential value in clinical practice. 
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31394177","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","MIR-200 GENE EXPRESSION POSITIVE","failed biomarker"
"130","CDK4/ 6INHIBITOR",NA,"BREAST CANCER","Rb, cyclin, E1, PIK3CA","others, others, others, others","positive, positive, positive, positive","OR,OR,OR","patients","31396487","Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice.","Here we present selected mechanisms of resistance to CDK4/6 inhibitors, largely focussing on roles of Rb, cyclin E1, and the PIK3CA pathway, with discussion of associated biomarkers which have been investigated and applied in recent pre-clinical and clinical studies
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31396487","Drug names are mentioned in the abstract.","NA","NA","ENSG00000139687, ENSG00000145386, ENSG00000114200, ENSG00000121879","MONDO_0007254","RB OTHERS POSITIVE OR CYCLIN OTHERS POSITIVE OR E1 OTHERS POSITIVE OR PIK3CA OTHERS POSITIVE","failed drug"
"131","NA",NA,"BREAST CANCER","miRs,TSmiRs","gene expression, gene expression","positive, positive","OR","patients","31400480","Effect of a high-intensity interval training on serum microRNA levels in women with breast cancer undergoing hormone therapy. A single-blind randomized trial.","HITT could amplify the decrease and/or increase in expression of
miRs associated with HT in women with breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/?term= 31400480","Drug names are mentioned in the abstract.","NA","56956252","NA, NA","MONDO_0007254","MIRS GENE EXPRESSION POSITIVE OR TSMIRS GENE EXPRESSION POSITIVE","failed biomarker"
"132","NA",NA,"BREAST CANCER","PRDXs","gene expression","positive",NA,"patients","31402980","Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer.","Our findings systematically elucidate the expression profiles and
distinct prognostic values of PRDXs in BrCa, which might provide novel
therapeutic targets and potential prognostic biomarkers for BrCa patients.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31402980","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","PRDXS GENE EXPRESSION POSITIVE","failed biomarker"
"133","NA",NA,"BREAST CANCER",NA,NA,NA,NA,NA,"31406940","The cardiotoxicity effect of different chemotherapeutic regimens in Iraqi patients with breast cancer: A follow up study.",NA,"https://www.ncbi.nlm.nih.gov/pubmed/?term=31406940",NA,"NA","56956252","ENSG00000183023","MONDO_0007254","NA NA NA","no biomarker"
"134","NA",NA,"INVASIVE BREAST CANCER",NA,NA,NA,NA,NA,"31414006","Racial Disparity Among Women Diagnosed With Invasive Breast Cancer in a Large Integrated Health System.",NA,"https://www.ncbi.nlm.nih.gov/pubmed/?term=31414006",NA,"NA","56956252","ENSG00000183023","EFO_1000307","NA NA NA","no biomarker"
"135","NA",NA,"CHRONIC LOW-GRADE
INFLAMMATION AND CANCER.","IL-6,CRP
","protein expression, protein expression
","positive, positive","OR
","patients","31414667","Association Between the Use of a Mobile Health Strategy App and Biological Changes in Breast Cancer Survivors: Prospective Pre-Post Study.","In conclusion, through the results of this study, we hypothesize that there is a possible association between an mHealth energy balance monitoring strategy and biological changes in BCSs. 
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31414667","No drug was mentioned in the abstract.","NA","56956252","ENSG00000136244, ENSG00000132693","MONDO_0016680","IL-6 PROTEIN EXPRESSION POSITIVE OR CRP PROTEIN EXPRESSION POSITIVE","pass"
"136","NA",NA,"OVARIAN CANCER",NA,NA,NA,NA,"patients","31419925","Translational Theragnostic of Ovarian Cancer: Where do we stand?",NA,"https://www.ncbi.nlm.nih.gov/pubmed/?term=31419925","No drug was mentioned in the abstract.","NA","56956252","ENSG00000183023","MONDO_0008170","NA NA NA","no biomarker"
"137","NA",NA,"BREAST CANCER","miR-155,MAPK7","gene expression, gene expression","positive, positive","AND","patients","31424663","MicroRNA-155regulates the proliferation and metastasis of human breast cancers by targeting MAPK7.","Bioinformatic analysis revealed MAPK7 to be the potential target of miR-155.Taken together, miR-155 may prove essential in the management of
breast cancer.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31424663","No drug was mentioned in the abstract.","NA","56956252","NA, ENSG00000166484","MONDO_0007254","MIR-155 GENE EXPRESSION POSITIVE AND MAPK7 GENE EXPRESSION POSITIVE","failed biomarker"
"138","DOXORUBICIN",NA,"BREAST CANCER","CDK1, CCNA2, TOP2A, CCNB1, KIF11, MELK","gene expression, gene expression, gene expression, gene expression, gene expression,gene expression","positive, positive, positive, positive, positive, positive","OR,OR,OR,OR,OR","patients","31428132","Identification of Potential Crucial Genes and Key Pathways in Breast Cancer Using Bioinformatic Analysis.","These results revealed that
mitotic cell cycle and epithelial-to-mesenchymal transition pathway could be potential pathways accounting for the progression in breast cancer, and CDK1,
CCNA2, TOP2A, CCNB1, KIF11, and MELK may be potential crucial genes.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31428132","Drug names are mentioned in the abstract.","DB00997","443939","ENSG00000170312, ENSG00000145386, ENSG00000131747, ENSG00000134057, ENSG00000138160, ENSG00000165304","MONDO_0007254","CDK1 GENE EXPRESSION POSITIVE OR CCNA2 GENE EXPRESSION POSITIVE OR TOP2A GENE EXPRESSION POSITIVE OR CCNB1 GENE EXPRESSION POSITIVE OR KIF11 GENE EXPRESSION POSITIVE OR MELK GENE EXPRESSION POSITIVE","pass"
"139","NA",NA,"BREAST CANCER BRAIN METASTASIS","α2,6-linked sialic acids","metabolite abundance","positive",NA,"animal","31430160","Revealing the Biological Attributes of N-Glycan Isomers in Breast Cancer Brain Metastasis Using Porous Graphitic Carbon (PGC) Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).","Furthermore, the increase of the α2,6-sialylation level in 231BR likely
contributes to the passage of breast cancer cells through the blood-brain barrier, thus facilitating breast cancer brain metastasis. Meanwhile, the
upregulation of highly sialylated glycan isomers with α2,6-linked sialic acids were found to be associated with breast cancer metastasis","https://www.ncbi.nlm.nih.gov/pubmed/?term=31430160","The in vivo model was not stated in the abstract.","NA","56956252","NA, NA","MONDO_0007254","failed","failed biomarker,failed term"
"140","NA",NA,"MISING",NA,NA,NA,NA,NA,"31431362","Identification of side arm-modified DOTA scaffolds as multi-site binding ligands for cancer cells over normal cells.",NA,"https://www.ncbi.nlm.nih.gov/pubmed/?term=31431362",NA,"NA","56956252","ENSG00000183023","NA","NA NA NA","no biomarker,failed disease"
"141","NA",NA,"MISING",NA,NA,NA,NA,NA,"31440080","Evaluating the prognostic significance of tumor-infiltrating lymphocytes in solid tumor: practice of a standardized method from the International Immuno-Oncology Biomarkers Working Group.",NA,"https://www.ncbi.nlm.nih.gov/pubmed/?term=31440080",NA,"NA","56956252","ENSG00000183023","NA","NA NA NA","no biomarker,failed disease"
"142","NA",NA,"BREAST CANCER","CRP,HbA1c","protein expression, protein expression","positive, positive","AND","patients","31443226","Associations between Dietary Acid Load and Biomarkers of Inflammation and Hyperglycemia in Breast Cancer Survivors.","Our study identifies a novel dietary factor that may lead to inflammation and hyperglycemia, both of which are strong risk factors for breast cancer recurrence and comorbidities.
","https://www.ncbi.nlm.nih.gov/pubmed/?term= 31443226","No drug was mentioned in the abstract.","NA","56956252","ENSG00000132693, NA","MONDO_0007254","CRP PROTEIN EXPRESSION POSITIVE AND HBA1C PROTEIN EXPRESSION POSITIVE","pass"
"143","NA",NA,"BREAST CANCER","tDR-7816,tDR-5334,tDR-4733","gene expression, gene expression, gene expression","positive, positive, positive","AND, AND","breast cancer cell lines","31535382","Serum tRNA-derived fragments (tRFs) as potential candidates for diagnosis of nontriple negative breast cancer.","Our results provide a rationale for using circulating tDR-7816 expression as a novel potential biomarker for the diagnosis of patients with early non-TNBC.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31535382","No drug was mentioned in the abstract.","NA","56956252","NA, NA, NA","MONDO_0007254","TDR-7816 GENE EXPRESSION POSITIVE AND TDR-5334 GENE EXPRESSION POSITIVE AND TDR-4733 GENE EXPRESSION POSITIVE","failed biomarker"
"144","NA",NA,"BREAST CANCER","miRNA-141","gene expression","positve",NA,"patients","31532182","Multimode MicroRNA Sensing via Multiple Enzyme-Free Signal Amplification and Cation-Exchange Reaction.","In this work, miRNA-141 was selected as a representative target
","https://www.ncbi.nlm.nih.gov/pubmed/?term= 31532182",NA,"NA","56956252","NA","MONDO_0007254","MIRNA-141 GENE EXPRESSION POSITVE","failed biomarker"
"145","NA",NA,"BREAST CANCER",NA,NA,NA,NA,NA,"31534156","Multi-view based integrative analysis of gene expression data for identifying biomarkers.",NA,"https://www.ncbi.nlm.nih.gov/pubmed/?term=31534156",NA,"NA","56956252","ENSG00000183023","MONDO_0007254","NA NA NA","no biomarker"
"146","NA",NA,"BREAST CANCER","S100A8/A9,CA15-3","protein expression, protein expression","positive, positive","AND","patients","31528166","Clinical Value of Serum S100A8/A9 and CA15-3 in the Diagnosis of Breast Cancer.","According to our data as well as other observations, the S100A8/A9
heterodimer can be considered as a potential biomarker for the proper diagnosis and prognosis of breast cancer.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31528166","No drug was mentioned in the abstract.","NA","56956252","NA, NA","MONDO_0007254","S100A8/A9 PROTEIN EXPRESSION POSITIVE AND CA15-3 PROTEIN EXPRESSION POSITIVE","failed biomarker"
"147","NA",NA,"BREAST CANCER:","MSH2, MSH6 ,MLH1,PMS2","gene expression, gene expression, gene expression,gene expression","negative, negative, negative, negative","OR,OR,OR","patients","31522348","Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.","Breast cancer patients 
with MMR deficiency as assessed by immunohistochemistry may be good candidates for alternative treatment approaches such as immune checkpoint or CDK4 inhibitors.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31522348","No drug was mentioned in the abstract.","NA","56956252","ENSG00000095002, ENSG00000116062, ENSG00000076242, ENSG00000122512","MONDO_0007254","MSH2 GENE EXPRESSION NEGATIVE OR MSH6 GENE EXPRESSION NEGATIVE OR MLH1 GENE EXPRESSION NEGATIVE OR PMS2 GENE EXPRESSION NEGATIVE","pass"
"148","NA",NA,"MISING",NA,NA,NA,NA,NA,"31520518","Diffusion MRI of the breast: Current status and future directions.",NA,"https://www.ncbi.nlm.nih.gov/pubmed/?term=31520518",NA,"NA","56956252","ENSG00000183023","NA","NA NA NA","no biomarker,failed disease"
"149","NA",NA,"BREAST CANCER","ABC transporters","protein expression","positive",NA,"patients","32010961","Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.","Multidrug resistance due to facilitated drug efflux mediated by ATP-binding cassette (ABC) transporters is a main cause for failure of cancer therapy.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=32010961","No drug was mentioned in the abstract.","NA","56956252","NA","MONDO_0007254","ABC TRANSPORTERS PROTEIN EXPRESSION POSITIVE","failed biomarker"
"150","CAPIVASERTIB",NA,"ER+ INVASIVE BREAST CANCER","ESR1, pPRAS40, pGSK3β, Ki6","protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive","AND, OR,OR","patients","31836609","Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).","Capivasertib 480 mg b.i.d. rapidly modulates key biomarkers of the
AKT pathway and decreases proliferation marker Ki67, suggesting future potential as an effective therapy in AKT-dependent breast cancers.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31836609","Drug names are mentioned in the abstract.","DB12218","25227436","ENSG00000091831, NA, NA, NA","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND PPRAS40 PROTEIN EXPRESSION POSITIVE OR PGSK3Β PROTEIN EXPRESSION POSITIVE OR KI6 PROTEIN EXPRESSION POSITIVE","pass"
"151","CAPIVASERTIB, PACLITAXEL",NA,"ESTROGEN RECEPTOR-POSITIVE ADVANCED OR METASTATIC BREAST CANCER","ESR1, ERBB2, PIK3CA","protein expression, protein expression, mutation","positive, negative, positive","AND, AND","patients","30860570","BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.","Capivasertib had no apparent impact on the tolerability and dose intensity of paclitaxel. Adding capivasertib to weekly paclitaxel did not prolong PFS in the overall population or PIK3CA+ sub-population of ER+/HER2-advanced/metastatic breast cancer patients.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=30860570","Drug names are mentioned in the abstract.","DB12218,DB01229","25227436, 36314","ENSG00000091831, ENSG00000141736, ENSG00000121879","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND PIK3CA MUTATION POSITIVE","pass"
"152","CAPIVASERTIB",NA,"OESTROGEN RECEPTOR-POSITIVE BREAST CANCER","PTEN, PIK3CA","mutation","positive, positive","OR","patients","32035020","Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
","Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advanced breast cancer.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=32035020","Drug name is mentioned in the abstract.","DB12218","25227436","ENSG00000171862, ENSG00000121879","MONDO_0007254","failed","failed term"
"153","CAPIVASERTIB",NA,"TNBC","PI3K,AKT,PTEN","protein expression,   others, gene expression","positive, positive, negative","OR,OR,OR","patients","31841354","Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.","Addition of the AKT inhibitor capivasertib to first-line paclitaxel
therapy for TNBC resulted in significantly longer PFS and OS. Benefits were more  pronounced in patients with PIK3CA/AKT1/PTEN-altered tumors. Capivasertib
warrants further investigation for treatment of TNBC.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31841354","Drug name is mentioned in the abstract.","DB12218","25227436","ENSG00000121879, ENSG00000166971, ENSG00000171862","NA","failed","failed disease,failed term"
"154","MK-2206",NA,"BREAST CANCER","PIK3CA, AKT, PTEN","mutation, mutation, gene expression","positive, positive, negative","OR,OR,OR","patients","31277699","Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.","MK-2206 monotherapy had limited clinical activity in advanced breast
cancer patients selected for PIK3CA/AKT1 or PTEN mutations or PTEN loss. This may, in part, be due to inadequate target inhibition at tolerable doses in heavily pre-treated patients with pathway activation, as well as tumor heterogeneity and evolution in markers such as PTEN conferring challenges in patient selection.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31277699","Drug name is mentioned in the abstract.","NA","24964624","ENSG00000121879, ENSG00000166971, ENSG00000171862","MONDO_0007254","failed","failed term"
"155","LAPATINIB",NA,"HER3-HIGH BREAST CANCER","
EGFR, HER4,  ERBB2,HER3, Ki67,ESR1, PGR, Pakt, PERK, Stathmin","gene expression, gene expression, gene expression, gene expression, protein expression,protein expression,protein expression,protein expression,protein expression,protein expression","positive,positive, positive,positive, positive,negative, negative,negative, negative,negative","AND,AND,AND,AND,AND,OR,OR,OR,OR,OR,OR","patients","25398453","Antiproliferative Effect of Lapatinib in HER2-Positive and HER2Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).","Lapatinib has antiproliferative effects in a subgroup of HER2(-) nonamplified tumors characterized by high HER3 expression. The possible role of high HER2:HER3 heterodimers in predicting response to lapatinib merits investigation in HER2(-) tumors.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=25398453","Drug name is mentioned in the abstract.complicated","DB01259","208908","ENSG00000146648, ENSG00000178568, ENSG00000141736, ENSG00000065361, ENSG00000148773, ENSG00000091831, ENSG00000082175, NA, ENSG00000172071, ENSG00000117632","MONDO_0007254","failed","failed term"
"156","NA",NA,"ESTROGEN RECEPTOR-POSITIVE BREAST CANCER","ESR1,PI3K,mTOR","protein expression, protein expression, others","positive, positive,positive","AND,AND,AND","patients","19380449","Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.","Everolimus significantly increased letrozole efficacy in neoadjuvant 
therapy of patients with ER-positive breast cancer.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=19380449","No drug was mentioned in the abstract.","NA","56956252","ENSG00000091831, ENSG00000121879, ENSG00000198793","EFO_1000649","failed","failed term"
"157","PAN-PI3K INHIBITOR",NA,"BREAST CANCER","ERBB2, PI3K","protein expression, protein expression","negative, positive","AND","patients","28576675","Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): arandomised, double-blind, placebo-controlled, phase 3 trial.","PI3K inhibition combined
with endocrine therapy is effective in postmenopausal women with
endocrine-resistant, hormone receptor-positive and HER2-negative advanced breast  cancer. 
","https://www.ncbi.nlm.nih.gov/pubmed/?term=28576675","Drug name is mentioned in the abstract.","NA","NA","ENSG00000141736, ENSG00000121879","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND PI3K PROTEIN EXPRESSION POSITIVE","failed drug"
"158","NA",NA,"HER2-POSITIVE, ER-POSITIVE BREAST CANCER","ERBB2,ESR1, RB1","protein expression, protein expression, protein expression","negative, negative, negative","AND,AND","patients","29326029","Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.","Triple targeting of ER, HER2, and RB1 in HER2-positive and ER-positive breast cancer could be an effective chemotherapy-free treatment strategy. 
","https://www.ncbi.nlm.nih.gov/pubmed/?term=29326029","No drug was mentioned in the abstract.","NA","56956252","ENSG00000141736, ENSG00000091831, ENSG00000139687","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND RB1 PROTEIN EXPRESSION NEGATIVE","pass"
"159","RAD001",NA,"BREAST CANCER","mTOR","protein expression",NA,NA,"patients","20941539","The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.","mTOR plays a key role in tumor cell cycle control, proliferation, and survival. RAD001 (everolimus) is a novel macrolide that inhibits mTOR and thus downstream signaling pathways. 
","https://www.ncbi.nlm.nih.gov/pubmed/?term=20941539","Drug name is mentioned in the abstract.","NA","6442177","ENSG00000198793","MONDO_0007254","MTOR PROTEIN EXPRESSION NA","pass"
"160","LAPATINIB",NA,"HER-2-NEGATIVE EARLY BREAST CANCER","Ki67,HER-3, FOXO3a, FOXM1, p-AKT","protein expression, protein expression, protein expression, protein expression,  protein expression","negative, negative, negative,  negative,  negative","OR,OR,OR,OR","patients","23233650","An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study).","Overall, a pre-surgical course of lapatinib monotherapy had little
effect on this group of patients; however, in subsets of patients, especially those with HER-3-positive tumors, we observed either reduction in proliferation (Ki67) or tumor size; EGFR/ER status had no impact
","https://www.ncbi.nlm.nih.gov/pubmed/?term=23233650","Drug name is mentioned in the abstract.","DB01259","208908","ENSG00000148773, NA, ENSG00000118689, ENSG00000111206, NA","MONDO_0007254","KI67 PROTEIN EXPRESSION NEGATIVE OR HER-3 PROTEIN EXPRESSION NEGATIVE OR FOXO3A PROTEIN EXPRESSION NEGATIVE OR FOXM1 PROTEIN EXPRESSION NEGATIVE OR P-AKT PROTEIN EXPRESSION NEGATIVE","pass"
"161","MK-2206",NA,"ER-POSITIVE AND HER2-NEGATIVE BREAST CANCER","PIK3CA, AKT","geneexpression, protein expression","positive, positive","OR","patients","28874413","A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.","MK-2206 is unlikely to add to the efficacy of anastrozole
alone in PIK3CA-mutant ER+ breast cancer and should not be studied further in the target patient population. 
","https://www.ncbi.nlm.nih.gov/pubmed/?term=28874413","Drug name is mentioned in the abstract.","NA","24964624","ENSG00000121879, ENSG00000166971","MONDO_0007254","PIK3CA GENEEXPRESSION POSITIVE OR AKT PROTEIN EXPRESSION POSITIVE","pass"
"162","AZD 5363, AZD 8931",NA,"HER2-AMPLIFIED BREAST CANCER","ERBB2,HER3,
PI3K, AKT, mTOR, ERK","protein expression & amplification, protein expression, others, others, others, others","positive, positive, positive, positive, positive, positive","AND,
,OR,OR,OR,OR","patients","26095475","Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.","We conclude that the activity of AZD5363 in HER2-amplified breast
cancer cells is enhanced by the addition of AZD8931 and that dual targeting of AKT and EGFR,HER,HER3 signalling is an attractive treatment option to be
explored in the clinic.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=26095475","No drug was mentioned in the abstract.","NA,NA","25227436, 11488320","ENSG00000141736, ENSG00000065361, ENSG00000121879, ENSG00000166971, ENSG00000198793, ENSG00000169032","MONDO_0007254","failed","failed term"
"163","IPATASERTIB, PACLITAXEL",NA,"TRIPLE-NEGATIVE BREAST CANCER","PI3K/AKT","others","negative, negative","OR","patients","28800861","Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre,randomised,double-blind, placebo-controlled, phase 2 trial.","To our knowledge, these are the
first results supporting AKT-targeted therapy for triple-negative breast cancer.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=28800861","Drug name is mentioned in the abstract.","DB11743,DB01229","24788740, 36314","ENSG00000170820","EFO_0005537","failed","failed term"
"164","SPRMS",NA,"BREAST CANCER","PI3K/AKT/mTOR","others","negative, negative, negative","OR/OR","patients","29223745","Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.","The efficacy of buparlisib supports the rationale for the use of PI3K inhibitors plus endocrine therapy in patients with PIK3CA mutations.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=29223745","No drug was mentioned in the abstract.","NA","NA","NA","MONDO_0007254","failed","failed drug,failed biomarker,failed term"
"165","NA",NA,"BREAST CANCER","Ki67,ERBB2","protein expression, protein expression","positive, negative","OR","patients","31570566","Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate.","Selective progesterone receptor modulators (SPRMs) show preclinical activity against hormone-sensitive breast cancer, but have not been tested in patients with early, treatment-naïve tumors.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31570566","No drug was mentioned in the abstract.","NA","56956252","ENSG00000148773, ENSG00000141736","MONDO_0007254","KI67 PROTEIN EXPRESSION POSITIVE OR ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"166","VITAMIN D",NA,"BREAST CANCER","IGF-1,IGF-1/IGFBP-3","protein expression, protein expression, protein expression","positive, positive, positive","AND,AND","patients","31138522","Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOGS0812).","This trial does not support the use of vitamin D supplementation for breast cancer risk reduction.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=31138522","Drug name is mentioned in the abstract.","DB11094","5280795","ENSG00000259384, NA","MONDO_0007254","failed","failed term"
"167","NA",NA,"POSTMENOPAUSAL BREAST CANCER","ER-β, ER-α, Ki 67","protein expression, protein expression,  protein expression","positive, positive, positive","AND,OR","patients","24047421","Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.","The role of estrogen receptor beta (ER-β) in breast cancer (BC)
remains unclear. Some studies have suggested that ER-β may oppose the actions of  estrogen receptor alpha (ER-α), and clinical evidence has indicated that the loss of ER-β expression is associated with a poor prognosis and resistance to
endocrine therapy.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=24047421","No drug was mentioned in the abstract.","NA","56956252","NA, NA, ENSG00000148773","MONDO_0007254","ER-Β PROTEIN EXPRESSION POSITIVE AND ER-Α PROTEIN EXPRESSION POSITIVE OR KI 67 PROTEIN EXPRESSION POSITIVE","failed biomarker"
"168","LAPATINIB",NA,"HER-2-POSITIVE BREAST CANCER","EGFR,HER2,Ki67,PTEN","protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive","AND,AND, AND","patients","21685235","Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.","Short-term lapatinib decreased cell proliferation in DIN, DH, and invasive HER-2-positive(especially ER-negative) breast cancer, thus providing the rationale for further 
clinical development of lapatinib for breast cancer prevention in high-risk
patients, including those with HER-2-positive DIN.
","https://www.ncbi.nlm.nih.gov/pubmed/?term=21685235","Drug name is mentioned in the abstract.","DB01259","208908","ENSG00000146648, ENSG00000141736, ENSG00000148773, ENSG00000171862","MONDO_0007254","EGFR PROTEIN EXPRESSION POSITIVE AND HER2 PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE AND PTEN PROTEIN EXPRESSION POSITIVE","pass"
"169","EVEROLIMUS, TRASTUZUMAB",NA,"HER2-POSITIVE ADVANCED BREAST CANCER","ESR1, PGR, ERBB2","protein expression, protein expression, protein expression","negative, negative, positive","AND/OR, AND","patients","26092818","Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): aphase 3, randomised, double-blind, multicentre trial.","mTOR inhibition reverses trastuzumab resistance via the
hyperactivated PIK/AKT/mTOR pathway due to PTEN loss, by sensitising PTEN-deficient tumours to trastuzumab. 
","https://www.ncbi.nlm.nih.gov/pubmed/?term=26092818","Drug name is mentioned in the abstract.","DB01590,DB00072","6442177, 3001322","ENSG00000091831, ENSG00000082175, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION NEGATIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"170","BEVACIZUMAB",NA,"BREAST CANCER","
VEGF-A
","
protein expression
","positive",NA,"others","31564802","An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?","Current evidences indicate some predictive values for genetic variants, molecular imaging, VEGF pathway factors or associated factors in peripheral blood and gene profiling. ","https://www.ncbi.nlm.nih.gov/pubmed/?term=31564802",NA,"DB00112","NA","ENSG00000112715","MONDO_0007254","VEGF-A PROTEIN EXPRESSION POSITIVE","pass"
"171","NA",NA,"BREAST CANCER",NA,NA,NA,NA,"patients","31562584","Semi-automatic segmentation from intrinsically-registered 18F-FDG-PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE-MRI.","Using PET/MRI, tumor area and mean ADC value estimated with a GMM-PET can replicate manual DCE tumor definition from MRI for monitoring neoadjuvant treatment response in breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31562584",NA,"NA","56956252","ENSG00000183023","MONDO_0007254","NA NA NA","no biomarker"
"172","NA",NA,"BREAST CANCER","miRNA","gene expression","positive",NA,"cells","31549595","Determination of Dysregulated miRNA Expression Levels by qRT-PCR after the Application of Usnic Acid to Breast Cancer.","These miRNAs might play important regulatory roles in the tumorigenesis and development of breast cancer and they could serve as prognostic predictors for breast cancer patients.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31549595",NA,"NA","56956252","ENSG00000037897","MONDO_0007254","MIRNA GENE EXPRESSION POSITIVE","pass"
"173","CABOZANTINIB, TRASTUZUMAB",NA,"BREAST CANCER BRAIN METASTASES (BCBM)","VEGFR 2","protein expression","positive",NA,"patients","31541381","A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.","Cabozantinib had insufficient activity in heavily pretreated BCBM patients. Biomarker analysis showed that cabozantinib had antiangiogenic activity and increased tissue hypoxia.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31541381",NA,"DB08875,DB00072","25102846, 3001322","ENSG00000165197","MONDO_0007254","VEGFR 2 PROTEIN EXPRESSION POSITIVE","pass"
"174","NA",NA,"TRIPLE NEGATIVE BREAST CANCER (TNBC)","ESR1, PGR, ERBB2","protein expression,protein expression,protein expression","negative, negative, negative","AND,AND","patients","31536530","Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database.","NAC may be inferior to AC in TNBC, likely related to the high frequency of non-pCR following NAC.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31536530",NA,"NA","56956252","ENSG00000091831, ENSG00000082175, ENSG00000141736","EFO_0005537","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"175","TAXANE, ANTHRACYCLINE",NA,"HER2-NEGATIVE BREAST CANCER","ERBB2, CA12, FOXA1,
MLPH, XBP1,
GATA3, MAGED 2","protein expression,  gene expression, gene expression, gene expression, gene expression, gene expression, gene expression","positive, positive, positive, positive, positive, positive, positive","AND, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR,","others","31534839","Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy.","Genes of CA12, FOXA1, MLPH, XBP1, GATA3 and MAGED2 might serve as novel biomarkers predicting chemotherapeutic response and prognosis for HER2-negative breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31534839",NA,"NA,NA","9548828, NA","ENSG00000141736, ENSG00000074410, ENSG00000129514, ENSG00000115648, ENSG00000100219, ENSG00000107485, NA","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND CA12 GENE EXPRESSION POSITIVE AND/OR FOXA1 GENE EXPRESSION POSITIVE AND/OR MLPH GENE EXPRESSION POSITIVE AND/OR XBP1 GENE EXPRESSION POSITIVE AND/OR GATA3 GENE EXPRESSION POSITIVE AND/OR MAGED 2 GENE EXPRESSION POSITIVE","pass"
"176","NA",NA,"BREAST CANCER PRECLINICAL MODELS.","PIK3CA","mutation","psitive",NA,"cell line","31534012","Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.","These data suggest that development of taselisib in breast cancer should occur in a PIK3CA-mutant setting with cotreatments determined by the specific subtypes under investigation.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31534012",NA,"NA","56956252","ENSG00000121879","MONDO_0007254","PIK3CA MUTATION PSITIVE","pass"
"177","NA",NA,"BREAST CANCER","
SNP","
polymorphism","positive",NA,"patients","31519601","The Influence of Adjuvant Radiotherapy and Single Nucleotide Polymorphisms on Circulating Immune Response Cell Numbers and Phenotypes of Patients With Breast Cancer.","The combination of RT and immunotherapy might provide optimal treatment for cancer patients.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31519601",NA,"NA","56956252","ENSG00000145901","MONDO_0007254","SNP POLYMORPHISM POSITIVE","pass"
"178","ADRIAMYCIN",NA,"P53-MUTATED BREAST CANCER","p53, miR-30c,
FANCF, REV1","mutation, gene expression,
protein expression, protein expression","positive, positive, positive, positive","AND,AND,AND","cell line","31511498","Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.","The novel miRNA-mediated pathway that regulates chemoresistance in breast cancer will facilitate the development of novel therapeutic strategies.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31511498",NA,"NA","443939","ENSG00000141510, NA, ENSG00000183161, ENSG00000135945","MONDO_0007254","P53 MUTATION POSITIVE AND MIR-30C GENE EXPRESSION POSITIVE AND FANCF PROTEIN EXPRESSION POSITIVE AND REV1 PROTEIN EXPRESSION POSITIVE","pass"
"179","TAMOXIFEN",NA,"BREAST CANCER","ESR1, PGR","protein expression, protein expression","positive,positive","AND/OR,",NA,"31504126","Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.","Continuous BCI (H/I) levels predicted the magnitude of benefit from extended tamoxifen, whereas centralized ER and PR did not.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31504126",NA,"DB00675","2733526","ENSG00000091831, ENSG00000082175","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"180","TRASTUZUMAB",NA,"HER-2+ ADVANCED BREAST CANCER","ERBB2","protein expression","positive",NA,"patients","31500588","Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.","Durable clinical benefit can be achieved with trastuzumab monotherapy in a subgroup of HER2-positive patients with advanced disease and it is predictive for longer OS.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31500588",NA,"DB00072","3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"181","NA",NA,"BREAST CANCER","pZIP 7","protein expression","positive",NA,"cell line","31483418","Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer.","This evidence suggests that pZIP7 might have potential as a biomarker of acquired resistance to such anti-hormones in breast cancer","https://www.ncbi.nlm.nih.gov/pubmed/?term=31483418",NA,"NA","56956252","NA","MONDO_0007254","PZIP 7 PROTEIN EXPRESSION POSITIVE","failed biomarker"
"182","NA",NA,"ER+ BREAST CANCER","CDC20mRNA","gene expression","positive",NA,"patients","31471836","CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.","This study shows that the CDC20 could act as potential predictive biomarker of poor response to endocrine therapy in ER+ breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31471836",NA,"NA","56956252","NA","EFO_1000650","CDC20MRNA GENE EXPRESSION POSITIVE","failed biomarker"
"183","NA",NA,"TRIPLE NEGATIVE BREAST CANCER","ESR1, PGR, ERBB2
","protein expression, protein expression, protein expression,","negative,negative,negative",NA,"patients","31467642","Incorporating biomarkers to improve statistical power of immunotherapeutic neoadjuvant clinical trials in patients with triple-negative breast cancer.","In this article, a stepwise hypothesis testing procedure is proposed to combine a continuous tumor biomarker with the conventional binary endpoint in a two-arm randomized phase II superiority trial to improve statistical power.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31467642",NA,"NA","56956252","ENSG00000091831, ENSG00000082175, ENSG00000141736","EFO_0005537","failed","failed term"
"184","NA",NA,"TRIPLE NEGATIVE BREAST CANCER.","ESR1, PGR, ERBB2
","protein expression, protein expression, protein expression,","negative,negative,negative","AND,AND","patients","31443516","Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge.","The evidence presented in this review outlines the role of crucial pathways in TNBC survival following chemotherapy treatment and highlights the importance of using combinatorial drug strategies and incorporating biomarkers in clinical studies.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31443516",NA,"NA","56956252","ENSG00000091831, ENSG00000082175, ENSG00000141736","EFO_0005537","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"185","NA",NA,"BREAST CANCER","SLCO1B3","mutation",NA,NA,"patients","31434449","Association study of genetic variations in SLCO1B3 gene with prognosis in breast cancer patients treated with neoadjuvant chemotherapy of TA regimen.","The variations of rs11045689 and rs73241801 in SLCO1B3 gene were significantly associated with prognosis of BC patients treated with neoadjuvant chemotherapy of TA regimen, which might serve as biomarkers for predicting prognosis of BC patients treated with neoadjuvant chemotherapy.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31434449",NA,"NA","56956252","ENSG00000111700","MONDO_0007254","SLCO1B3 MUTATION NA","pass"
"186","AROMATASE INHIBITORS, TAMOXIFEN",NA,"ER-POSITIVE BREAST CANCER","ESR1, ERBB2","protein expression, protein expression","positive, negative","AND","patients","31423426","Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer.","In this review, we discuss the most relevant evidence on the potential of NAE for ER+ breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31423426",NA,"NA,DB00675","NA, 2733526","ENSG00000091831, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","failed drug"
"187","BAZEDOXIFENE, ESTROGEN",NA,"BREAST CANCER","Volpara,
Ki-67,
IGF-1,
IGFBP3","others,
protein expression,protein expression,protein expression
","positive, positive, negative, negative","OR,AND,AND","patients","31420361","Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study.","Risk biomarkers included fully automated mammographic volumetric density (Volpara), benign breast tissue Ki-67 (MIB-1 immunochemistry), and serum levels of progesterone, IGF-1, and IGFBP3, bioavailable estradiol and testosterone.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31420361",NA,"DB06401,NA","154256, 448537","NA, ENSG00000148773, ENSG00000259384, ENSG00000146674","MONDO_0007254","VOLPARA OTHERS POSITIVE OR KI-67 PROTEIN EXPRESSION POSITIVE AND IGF-1 PROTEIN EXPRESSION NEGATIVE AND IGFBP3 PROTEIN EXPRESSION NEGATIVE","failed biomarker"
"188","NERATINIB",NA,"HER2-POSITIVE BREAST CANCER","TBCP-1,
HER 2","protein expression,
gene expression","positive, positive","AND","mouse","31409375","Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2","The TBCP-1 model recapitulates the spontaneous spread of HER2-positive breast cancer to the brain seen in patients and provides a unique tool to identify novel therapeutics and biomarkers.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31409375",NA,"DB11828","9915743","NA, ENSG00000141736","EFO_1000294","TBCP-1 PROTEIN EXPRESSION POSITIVE AND HER 2 GENE EXPRESSION POSITIVE","failed biomarker"
"189","BEVACIZUMAB, DOCETAXEL, CYCLOPHOSPHAMIDE",NA,"HER-2 NEGATIVE BREAST CANCER","VEGF,
cTnI,
MPO,
PlGF
","protein expression, protein expression, protein expression,
protein expression","negative, negative, negative, negative","OR/AND/OR","patients","31384312","Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.","We observed a low relapse rate in node-positive, HR+ patients; however, results in TN breast cancer were less encouraging.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31384312",NA,"DB00112,DB01248,DB00531","NA, 148124, 2907","ENSG00000112715, NA, ENSG00000005381, ENSG00000119630","MONDO_0007254","failed","failed term"
"190","NA",NA,"BREAST CANCER","PD-1","protein expression",NA,NA,"patients","31357142","Targeting PD-1 in cancer: Biological insights with a focus on breast cancer.","This review aims to shed light on the main principles of targeting PD-1 in breast cancer, from biology through its functional and clinical implications.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31357142",NA,"NA","56956252","ENSG00000265681","MONDO_0007254","PD-1 PROTEIN EXPRESSION NA","pass"
"191","NA",NA,"MBC","TK 1
CDK 4/6/9 mRNA","protein expression
gene expression","positive, positive, positive, positive","AND/ADN/AND","patients","31346846","Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.","Therefore, the present article addresses the role of the mRNA expression of thymidine kinase 1 (TK1), CDK4, 6 and 9 in plasma-derived exosomes and their relevance in the pharmacologic activity of CDK4/6i.","https://www.ncbi.nlm.nih.gov/pubmed/?term=31346846",NA,"NA","56956252","NA","NA","failed","failed biomarker,failed disease,failed term"
"192","NA",NA,"BREAST CANCER","PD-1, PD-L1","others","positive, positive","AND","cells
patients","31336685","PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review","In this review, we will report the results of the most recent studies evaluating immune checkpoint inhibitors in breast cancer.","https://www.gcbi.com.cn/gclib/html/pubmed/detail/31336685",NA,"NA","56956252","ENSG00000265681, ENSG00000120217","MONDO_0007254","failed","failed term"
"193","EVEROLIMUS, EXEMESTANE",NA,"ADVANCED BREAST CANCER","SP-D, YKL-40","protein expression, protein expression","positive, positive,","AND/OR","patients","31325105","Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane.","This study shows that everolimus-related ILD occurs frequently. Prospective monitoring of DLCOc in combination with measurement of serum SP-D and YKL-40 appear useful to discriminate ILD from other causes of respiratory symptoms","https://www.gcbi.com.cn/gclib/html/pubmed/detail/31325105",NA,"DB01590,DB00990","6442177, 60198","ENSG00000133661, ENSG00000133048","MONDO_0007254","SP-D PROTEIN EXPRESSION POSITIVE AND/OR YKL-40 PROTEIN EXPRESSION POSITIVE","pass"
"194","NA",NA,"EARLY-STAGE INVASIVE BREAST CANCER",NA,NA,NA,NA,NA,"31306037","Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update Summary",NA,"https://www.gcbi.com.cn/gclib/html/pubmed/detail/31306037","no abstract","NA","56956252","ENSG00000183023","MONDO_0007254","NA NA NA","no biomarker"
"195","NA",NA,"ER-POSITIVE BREAST CANCER","ESR1, epidermal growth factor receptor 2","protein expression, protein expression","positive, negative","AND","patients","31279611","Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.","Significantly higher rates of down-staging were achieved with NACT compared with NET when patients were matched. This study highlights the importance of establishing tumor biology and the need for biomarkers that can be used as predictive tools to inform treatment.","https://www.gcbi.com.cn/gclib/html/pubmed/detail/31279611",NA,"NA","56956252","ENSG00000091831, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND EPIDERMAL GROWTH FACTOR RECEPTOR 2 PROTEIN EXPRESSION NEGATIVE","pass"
"196","MK-2206",NA,"ADVANCED BREAST CANCER","ESR1, PGR, ERBB2, PIK3CA,AKT1, PTEN, Ki-67","protein expression, protein expression, protein expression,  mutation,mutation & protein expression, mutation, protein expression, protein expression","positive/negative, positive/negative, positive/negative, positive,positive, positive","AND, AND, AND, AND/OR, AND/OR, AND/OR,","patients","31277699","Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation","MK-2206 monotherapy had limited clinical activity in advanced breast cancer patients selected for PIK3CA/AKT1 or PTEN mutations or PTEN loss.","https://www.gcbi.com.cn/gclib/html/pubmed/detail/31277699","complecatted case","NA","24964624","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000121879, ENSG00000142208, ENSG00000171862, ENSG00000148773","MONDO_0007254","failed","failed term"
"197","TRASTUZUMAB",NA,"HER2+ BREAST CANCER","ERBB2, TGFBI","protein expression & amplification, methylation","positive,positive","AND","patients","31277676","Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.","Our results suggest for the first time an association between the epigenetic silencing of TGFBI by DNA methylation and trastuzumab resistance in HER2+ cell models. These results provide the basis for further clinical studies to validate the hypermethylation of TGFBI promoter as a biomarker of trastuzumab resistance in HER2+ breast cancer patients.","https://www.gcbi.com.cn/gclib/html/pubmed/detail/31277676",NA,"DB00072","3001322","ENSG00000141736, ENSG00000120708","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND TGFBI METHYLATION POSITIVE","pass"
"198","NA",NA,"BREAST CANCER","microRNA-21, microRNA-206, ER, PR, HER 2","gene expression, gene expression, protein expression, protein expression, protein expression","positive, positive, negative, negative, negative","AND/AND/AND/AND","patients","31276668","Correlation between microRNA-21, microRNA-206 and estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 in breast cancer","Both microRNA-21 and microRNA-206 closely correlate with ER, PR, and HER2 expression, which can be considered as clinical biomarkers","https://www.gcbi.com.cn/gclib/html/pubmed/detail/31276668",NA,"NA","56956252","ENSG00000283844, NA, ENSG00000091831, ENSG00000134551, ENSG00000141736","MONDO_0007254","failed","failed term"
"199","NA",NA,"BREAST CANCER","miR-148b-3p、miR-190b, miR-429","gene expression","positive, positive","AND/OR, AND/OR","cell lines","31281725","miR-148b-3p, miR-190b, and miR-429 Regulate Cell Progression and Act as Potential Biomarkers for Breast Cancer","The miR-148b-3p, miR-190b, and miR-429 may serve as potential diagnostic and prognostic markers for breast cancer. This study demonstrated the roles of these 3 miRNAs in the initiation and progression of breast cancer","https://www.gcbi.com.cn/gclib/html/pubmed/detail/31281725",NA,"NA","56956252","NA, NA","MONDO_0007254","failed","failed biomarker,failed term"
"200","NA",NA,"BREAST CANCER",NA,NA,NA,NA,"rat","31281771","Label-free molecular profiling for identification of biomarkers in carcinogenesis using multimodal multiphoton imaging.","Multimodal multiphoton imaging reveals and interrelates diverse carcinogenic signatures, identifying biomarkers that could serve as early molecular indicators for breast cancer diagnosis. This quantitative multimodal imaging methodology for molecular profiling of associated cancer biomarkers may have a broader impact in fundamental cancer research and future clinical applications.","https://www.gcbi.com.cn/gclib/html/pubmed/detail/31281771",NA,"NA","56956252","ENSG00000183023","MONDO_0007254","NA NA NA","no biomarker"
"201","NA",NA,"BREAST CANCER","TPX2,
KIF2C,
CDCA8,
BUB1B,
CCNA2","gene expression, gene expression, gene expression, gene expression, gene expression,","positive, positive, positive, positive, positive","AND/OR, AND/OR,AND/OR, AND/OR,  AND/OR","patients","31285741","Identification of five hub genes as monitoring biomarkers for breast cancer metastasis in silico","Five hub genes (TPX2, KIF2C, CDCA8, BUB1B, and CCNA2) associated with the risk of distant metastasis were extracted for further research, which might be used as biomarkers to predict distant metastasis of breast cancer. ","https://www.gcbi.com.cn/gclib/html/pubmed/detail/31285741",NA,"NA","56956252","ENSG00000088325, ENSG00000142945, ENSG00000134690, ENSG00000156970, ENSG00000145386","MONDO_0007254","failed","failed term"
